Index

Note: 'Page numbers followed by *"f"* indicate figures and *"t"* indicate tables and *"b"* indicate boxes.'

A

AABB. *See* American Association of Blood Banks (AABB)
AAV. *See* Adeno-associated virus (AAV)
Abiraterone, 42
Abiraterone acetate, 359–360
ABR. *See* Annual bleeding rate (ABR)
Academia industry partnerships, 344–348
Acellular tissue matrix, 248–249
Act on Safety of Regenerative Medicine (RM Act), 132, 133t
Activating receptors of NK cells, 95–96
Activation-induced cell death (AICD), 46
Acute leukocytic leukaemia, 652–653
Acute lymphoblastic leukaemia (ALL), 7–8, 304–305, 530, 750
Acute lymphocytic leukaemia (ALL), 19–20, 508
Acute myeloblastic leukaemia (AML), 19–20
Acute myeloid leukaemia (AML), 326–327
AD. *See* Alzheimer's disease (AD)
ADA. *See* Adenosine deaminase (ADA)
ADA-SCID. *See* Adenosine deaminase severe combined immunodeficiency (ADA-SCID)
Adaptimmune NY-ESO-1 programme, 378
Adaptimmune therapeutics, 332–333, 378
Adaptive immunity, 493–494
ADCC. *See* Antibody-dependent cell-mediated cytotoxicity (ADCC)
Adeno-associated virus (AAV), 18, 215–216, 229, 286, 291
  AAV-based gene therapy medicinal products, 292
  vectors, 414–415
Adenosine deaminase (ADA), 18–19, 659–660
  deficiency, 287
Adenosine deaminase severe combined immunodeficiency (ADA-SCID), 18–19, 715–716, 725b
Adenovirus (AdV), 17–18, 286, 288, 291
  AdV5, 288
Adicet Bio, Inc., 55–56
Adipocytes, 700–701
Administration costs, 706–707
Adoption of innovation, 673–674
Adoptive cell therapy, 56, 69–73, 80, 363–364
Adoptive T cell therapy, 377–378, 396–397, 583–584
Adult acute lymphoblastic leukaemia (Adult ALL), 309–315
Adult haemoglobin (HbA), 410
Adult roundworm (*Caenorhabditis elegans*), 451
Adult stem cells, 246–247
AdV. *See* Adenovirus (AdV)
Advanced Biohealing, 652
Advanced therapies, 200–201
  affordability of, 708–709
Advanced Therapies Manufacturing Action Plan, 671–672
Advanced therapy medicinal products (ATMPs), 587–588, 597–598, 598t, 649, 669–671
  regulation, 587–588
Advanced Therapy Treatment Centres (ATTCs), 681–682
Advanced Tissue Sciences (ATS), 649–650
Adverse events (AEs), 325
AEs. *See* Adverse events (AEs)
Affinity purification, 614
Afibromer techonology, 418–419
Ageing, 449–450, 453–455
  human cell senescence and immortalisation, 452
  human tissue regeneration regulation, 453–455
  perspectives, 456–458
  therapeutic strategies for, 455–456
Agency for Healthcare Research and Quality (AHRQ), 725b
Aggregated hyperphosphorylated tau, 472
AHRQ. *See* Agency for Healthcare Research and Quality (AHRQ)
AI. *See* Artificial Intelligence (AI)
AICD. *See* Activation-induced cell death (AICD)
Alanine aminotransferase (ALT), 415
Aldesleukin, 377
Alipogene tiparvovec. *See* Glybera
Alkylamines, 45

Alkylphosphates, 45
ALL. *See* Acute lymphoblastic leukaemia (ALL); Acute lymphocytic leukaemia (ALL)
Allen Cell Explorer, 198–199
Allocation in healthcare context, 591
Allogene therapeutics, 644
Allogeneic
  allogeneic cell-based therapies, 584
  bone marrow transplantation, 71
  CAR-T, 637–638
  cell replacement, 176–177
  MSCs, 10–11
  NK cells, 110–111
    transplantation, 124
  off-the-shelf replacement nerve tissue, 278–279
  products, 599–601
  γδ T cell therapy, 50–51
  T cells, 700
  therapies, 599–601, 602t–604t
  treatments, 251
Alpha thalassaemia Major. *See* Haemoglobin Bart's
ALT. *See* Alanine aminotransferase (ALT)
Alternative payment models, 730
Alzheimer's disease (AD), 216, 469, 708
  therapeutic opportunities for, 470–474
AMA. *See* American Medical Association (AMA)
Amazon, 426–427, 756
American Association of Blood Banks (AABB), 727
American Medical Association (AMA), 723b
American Society for Blood and Marrow Transplantation (ASBMT), 724
American Society of Clinical Oncology (ASCO), 43, 305–306
American Society of Haematology (ASH), 305–306
Aminobisphosphonates (N-BP), 45
AML. *See* Acute myeloblastic leukaemia (AML); Acute myeloid leukaemia (AML)
Amortisation payment model, 421–423, 729
AMT-060 gene therapy, 416–418
AMT-061 gene therapy, 416–418
Analytic hierarchy process, 619
Analytical reprogramming, 456
Angiogenesis, 517–518
Animal models, 175
Anisotropy creation in cellular hydrogels, 272–273
Annual bleeding rate (ABR), 414–415
2017 Annual meeting of American Society for Hematology (ASH2017), 633–634
Annuity. *See* Amortisation
Anti-CD19 receptor, 747–748
Anti-CTLA-4. *See* Anticytotoxic T lymphocyte antigen 4 (Anti-CTLA-4)
Anti-HIV CAR-T cells, 633
Anti-KIR antibody, 43
Anti-PD-1/PD-L1 therapies, 551–552
Anti-PD1. *See* Antiprogrammed death protein 1 (Anti-PD1)
Anti-T cell immunoglobulin 3 (Anti-TIM-3), 525–527
Anti-VEGF bevacizumab, 556–557
Antibody, 214
  anti-KIR antibody, 43
  antibody-dependent cellular cytotoxicity, 118–120
  antibody-dependent NK-mediated tumour killing, 118
  DC101, 695–696
  exception, 702
  KDR-1121, 695–696
Antibody-dependent cell-mediated cytotoxicity (ADCC), 42–43, 95–96, 110–111, 118–120
Anticancer immunotherapy development, 103
Anticytotoxic T lymphocyte antigen 4 (Anti-CTLA-4), 525–527
Antigen, 491–492, 639
  classes targetable by TCRs, 383t
  loading, 496
  processing, 494
Antigen-presenting cells (APC), 490, 525–527
Antigens, loading-up with, 497–498
Antiprogrammed death protein 1 (Anti-PD1), 525–527
'Antiresistance' strategies, 548–550
AP. *See* Artificial pancreas (AP)
APC. *See* Antigen-presenting cells (APC)
Approval processes of CAR-T therapy, 772
Archaeoglobus fulgidus, 220
Artificial Intelligence (AI), 183–200
  AI for drug discovery, development and repurposing, 192f
  deep learning, 187–189
  machine learning, 186–187
  neural networks, 188–189
  structured and unstructured data, 189
Artificial pancreas (AP), 158
Artificial restriction enzymes, 585

ASBMT. *See* American Society for Blood and Marrow Transplantation (ASBMT)
ASCO. *See* American Society of Clinical Oncology (ASCO)
ASCT. *See* Autologous stem cell transplant (ASCT)
Aseptic technique, 257–258, 260
ASH. *See* American Society of Haematology (ASH)
ASH2017. *See* 2017 Annual meeting of American Society for Hematology (ASH2017)
Asymptote, 655
Atezolizumab, 545–547
Athersys, 649–651
ATMPs. *See* Advanced therapy medicinal products (ATMPs)
ATS. *See* Advanced Tissue Sciences (ATS)
ATTCs. *See* Advanced Therapy Treatment Centres (ATTCs)
Autograft replacement, 274–276
  EngNT to, 276–278
Autologous
  adoptive cell transfer, 582
  CAR-expressing cells, 700
  CAR-T cell therapies, 753
  NK cells, 105–110
  products, 397–398, 599–601
  stem cells, 278
  T cell therapy, 72–73, 82
  γδ T cell therapy, 49–50
  therapies, 599–601, 602t–604t
    developers, 607–608
    transplantation, 123–124
Autologous stem cell transplant (ASCT), 390
Autolus, 636, 645
Automating, 344–348
Axicabtagene ciloleucel, 377, 583–584, 706–707, 720
Azidothymidine (AZT), 559–560
AZT. *See* Azidothymidine (AZT)

B

B-cell
  aplasia, 82–83, 338–339, 639
  lymphoma, 357
  malignancies, 82–83
    CAR-T cell therapy in, 83–84
B-cell maturation antigen (BCMA), 326–328
B2B. *See* Business to business (B2B)
B2P. *See* Business to provider/patient (B2P)
Bacille Calmette-Guérin vaccine, 581
Bacteriostatic–bacteriocidal antibiotic, 558–559
Baculovirus, 286
*BamH*1 enzyme, 232
Barriers to innovation, 663–669
B–associated transcript 3 (BAT3), 100
BAT3. *See* B–associated transcript 3 (BAT3)
4–1BB, 695–696
BBSRC. *See* Biotechnology and Biological Sciences Research Council (BBSRC)
BCMA. *See* B-cell maturation antigen (BCMA)
Bellicum Pharmaceuticals, 605, 635–636, 644
Benefit–risk assessment, 587
Best price, 427
Beta cells, 161, 166, 175
  effective insulin production by, 166
  endogenous insulin-producing, 157–158
  pancreatic progenitor cells, 174–176
  T1D recipients and, 161
Beta thalassaemia, 411–412
  cell and gene therapies for, 413t
Bevacizumab, 545–547
Big data, 184–200, 185f–186f
Big datasets, 190–200
  Allen Cell Explorer, 198–199
  automated image analysis algorithms, 199–200
  business models, 191
    working with 'Omics Insights', 191–196
  cell barcoding, 198
  deriving genomic insights in oncology, 195–196
  deriving novel pathway insights, 190–191
  drug
    discovery and development, 190–191
    disease interactions, 190–191
  Human Cell Atlas, 197–198
  machine learning to predict phenotype of stem cells, 198–199
  mechanobiology, 199
  network linkages, 191
  omics Data to Cell Therapies, 194–195
  revealer, 195–196
  single-cell sequencing of large populations, 196–198
  structural databases to design molecules, 190
(Bio)ethical research, 582
Biocompatible material, 270–271
BioCurate Pty Ltd. in Australia, 750–751
Bioengineered trachea, 244–245
Bioengineering, 244

Bioethics, 592–593
Bioindustry Association Regenerative Medicine Industry Group, 681
Biological safety cabinet (BSC), 260
Biologics, 214–215
Biologics, 527–530, 533–536, 565
Biologics License Application (BLA), 623
Biomarkers, 340–344, 394–396
  biomarker-based diagnostics, 525
  biomarker-based personalised medicines, 736
  current status in field of biomarker use, 344
  immune
    contexture, 396
    regulation, 395–396
  predicting efficacy of CAR-T cells, 341–342
  predicting toxicity, 342–344
  response assessments, 396
  T cells, 396
  target antigen expression, 395
Biomaterials, 247–256
  implanted scaffolds, 248–250
    3D bioprinting, 250
    acellular tissue matrix, 248–249
    manufactured scaffolds, 249–250
  types in tissue and organ regeneration, 248t
Biomimetic approach, 272
BioResource, 660
Biosafe Group, 655
Biosimulation for disease prevention and prediction, 198–200
Biotechnology and Biological Sciences Research Council (BBSRC), 667–668
Bipolar disorder (BPD), 462–465
  and facilitating drug development pipeline, 464–468
  lithium reveals BPD brain architectural abnormalities, 469–470
  using lithium to gain insight into, 463–464
  mania, 468f
  research workflow from patient cells to novel proteomic insight, 465f
Bispecific T cell engagers (BiTEs), 527–529, 540–541
Bisphosphonates, 52
BiTEs. *See* Bispecific T cell engagers (BiTEs)
BLA. *See* Biologics License Application (BLA)
'Black box' opaque, 189, 462
Black swan risk, 6
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), 637–638
Bleeding disorders, 413–420
Blood oxygen level dependent signal (BOLD signal), 474
Blood triglycerides, 716–717
Bluebird Bio, 378, 605, 643
Bluebird biosciences, 634
BM. *See* Bone marrow (BM)
BMN 270. *See* Valoctocogene roxaparvovec
BMT. *See* Bone marrow transplant (BMT)
Body-on-a-chip systems, 561
Boggs chamber, 162
BOLD signal. *See* Blood oxygen level dependent signal (BOLD signal)
Bone marrow (BM), 313
Bone marrow transplant (BMT), 71, 287, 707
BPD. *See* Bipolar disorder (BPD)
BPDCN. *See* Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Brain, 461–462
Brazil ANVISA, 358
Breakthrough designation, 392–393
Breakthrough Therapy, 325
BrHPP. *See* Bromohydrin Pyrophosphate (BrHPP)
Bromohydrin Pyrophosphate (BrHPP), 42–43, 48–49
Bruton's tyrosin kinase, 117
BSC. *See* Biological safety cabinet (BSC)
Burden of illness, 718–720
Business models, 191
Business to business (B2B), 752–757
Business to provider/patient (B2P), 752–757

C

C-lectin–related genes (Clr genes), 95
C# programming, 622
CAB. *See* Conditionally Active Biologics (CAB)
Cadaver-derived islets for T1D, 158–159
Caenorhabditis elegans. *See* Adult roundworm (*Caenorhabditis elegans*)
CALR. *See* Calreticulin (CALR)
Calreticulin (CALR), 525–527
Cancer, 69–71, 83–84, 287–288, 515–520. *See also* Solid tumour oncology
  cells, 689
    cancer cell–targeting drugs, 117–118
  hallmarks, 520–525, 522f–524f
  immunity cycle, 394–395

immunology, 41
immunosurveillance theory, 581
immunotherapy, 111, 551
genome-editing technologies in, 584–586
γδ T cells in, 48–53
incidence and mortality, 516f
inflammation and, 517f
NK cells and, 94–102
role in cancer immunosurveillance and immunoediting, 100–102
Cancer Genome Atlas, 195–196
Cancer-testis antigen (CTAs), 332
Capacity planning decision-making, 605, 607–608
Capital expenditure (CAPEX), 605
CAR. *See* Chimeric antigen receptor (CAR)
CAR-BCMA. *See* Chimeric antigen receptor-BCMA (CAR-BCMA)
CAR-T. *See* Chimeric antigen receptor T cell (CAR-T)
Carcinoembryonic antigen (CEA), 389, 584
Cardiomyocytes, 251–252
Cardiovascular disease, 287
Carisma therapeutics, 644
Carma therapeutics. *See* Carisma therapeutics
Cartesian approach, 91
Caspase 9 (Cas9), 222, 636
endonuclease technology, 585
Catapult Centres, 676, 678t
Catapult programme, 669–672
CCAM. *See* Classification Commune des Actes Médicaux (CCAM)
CCRM. *See* Commercialization of Regenerative Medicine (CCRM)
CD3 zeta chain, 695
CD4+ T cell line, 73–74
CD4ζ-modified CD4+ and CD8+ T cells, 303–304
CD8 receptor, 74–75
CD8+ T cells. *See* Cytotoxic T lymphocytes (CTL)
CD19 (cell surface protein), 326–327, 333–334, 348–357, 747–748
CD19-targeted therapies, 82–83
CD20 receptor, 326
CD22 receptor, 326
CD28 (endogenous protein), 76, 80–81, 693, 695–696
CD33 receptor, 326
CD34+ cell, 104–105
CD40 receptor, 554–555
CD44 receptor, 538–539
CD80 receptor, 529
CD94/NKG2 family, 95
CD123 receptor, 326
CD133 receptor, 538–539
CD138 receptor, 326–327
CDMO/CMO industry. *See* Contract Development Manufacturing Organisation industry (CDMO/CMO industry)
CDRs. *See* Complementarity-determining regions (CDRs)
CEA. *See* Carcinoembryonic antigen (CEA)
Celgene Corporation, 378, 643
Cell
barcoding, 198
biosimulation for disease prevention and prediction, 198–200
cell-based products, 747, 778–780
cell-derived principles, 437
cell-derived therapeutics, 438f
cell-inspired principles, 437
in cellular and tissue therapies, 245–247
adult stem cells, 246–247
ESCs, 246
perinatal stem cells, 247
infrastructure for cGMP Compliance, 260
manufacturing strategies, 52–53, 396–399, 584
replacement therapy, 158
suspension infusions, 261–262
Cell and Gene Therapy Catapult, 679
Cell death protein 1 (PD1), 331
Cell Design Labs, 635
Cell therapies, 4–5, 7–10, 250–251, 269, 409–410, 649–651, 675–676, 708–709, 712–713, 748, 749f. *See also* Engineered T cell therapy
using cadaver-derived islets and immune suppression for T1D, 158–159
challenges in commercialisation, 599
factors affecting innovation in, 666f
for haemophilia in preclinical and clinical phases, 417t
innovative payment models, 424t
iPSC as source material for, 173–174
manufacturing, 261–262
payment models for, 764–766, 765t

Cell therapies *(Continued)*
perspectives, 428–429
potential of immune system
industry, 54–57
obstacles to development and implementation of γδ T cell therapies, 53–54
perspectives, 57–58
potential for γδ T cells as primary effectors, 48–53
regulatory γδ T cells, 48
γδ T cells and recognition of malignant disease, 44–58
Vδ1+ T cells, 46–48
Vδ2+ T cells, 45–46
for SCD and beta thalassaemia, 413t
and value-based pricing implementation in United States, 420–428
Cell Therapy Technology and Innovation Centre (TIC), 660
CellChain platform, 757
Cellectis, 637–638, 644
CELL*for*CURE in France, 750
Cell–related encephalopathy syndrome (CRES), 393–394
Cellular biomaterials, 271–272
Cellular Biomedicine Group in China, 750
Cellular hydrogels
anisotropy creation in, 272–273
stabilisation of aligned, 273–274
Cellular self-alignment process, 273
Cellular switches, 635–636
Cellular therapy, 83, 659–660
cells in, 245–247
cellular/tissue apoptosis, 214
Celularity, 644
Center for Advanced Cellular Therapeutics, 750
Center for Medicare and Medicaid services (CMS), 420, 427–428, 723b, 724
Central nervous system (CNS), 391, 461–462, 507
Central processing unit (CPU), 186–188
Centralised payer and provider systems, 728–729
Centre for Islet Transplant Registry (CITR), 158–159
Cephalon, 651
Cetuximab, 119
CFRs. *See* Codes of Federal Regulation (CFRs)
CGD. *See* Chronic granulomatous disease (CGD)
cGMP. *See* Current good manufacturing practices (cGMP)
cGTPs. *See* Current Good Tissue Practices (cGTPs)
Checkpoint blockers, 121–123, 529, 531f
Checkpoint inhibitors, 559–560
successes in, 544–547
Chemistry, manufacturing and controls (CMC), 358–359
Chemokine (C–X–C motif) ligand 10 (CXCL10), 525–527
Chemotherapies, 559–560, 689. *See also* Cancer
Children's Hospital Of Philadelphia (CHOP), 315–320
Chimeric antigen receptor (CAR), 69, 73–77, 80, 94, 124, 378–379, 507–509, 583, 747–748
CAR-expressing immune cells, 691
CAR-NK cells, 136, 511, 527–532, 540–541, 547, 559–560, 562f–563f
clinical development status, 136, 139t
CAR–functionalised cell therapy in glioblastoma, 508–511
Chimeric antigen receptor T cell (CAR-T), 4–5, 41, 201–202, 224–226, 251, 291, 303, 461–462, 509, 525–527, 530–532, 551, 605, 652–653, 715–716, 747, 778–780
academia industry partnerships, 344–348
access and responsibility, 766–771
allogeneic CAR-T, 637–638
arrival of leukapheresis material, 755f
biomarkers, 340–344
Current Status in Field of Biomarker Use, 344
predicting efficacy of CAR-T cells, 341–342
predicting toxicity, 342–344
cell therapy companies, 640t–641t
challenges with CAR-T cell therapies, 333–340
clinical outcome of CD19 targeted CAR-T cells, 306–326
clinical trials with, 304–333, 305t
collaborating with hospitals, 757–761
critical innovation chunks of CAR-T S-Curve, 9–11, 10f
customer/business model, 753–757
financing history of leading companies, 642
first-generation CAR-T therapies, 633–634
for GBM, 509–511
global clinical development and regulatory approval, 751–752
healthcare systems and societal value, 762–763

history, 633
incumbents, 642–644
induced toxicities, 335–339
CRS, 335–338
insertional oncogenesis, 339
neurological toxicity, 338
replication-competent viruses, 339
on target toxicity, 338–339
initial trials of, 303–304
insufficient migration and infiltration, 540–541
limitations in ability, 539–540
manufacturing challenges, 339–340
Novartis journey to, 748–751, 758f
optimisation to improve antitumour efficacy, 331
patient and clinical value, 762
payment models for cell and gene therapies, 764–766, 765t
perspectives, 362–365, 645, 771–773
platform, 635–638
from process to product, 752–761
regulatory challenges and solutions, 357–359
research in China, 348–357
clinical trials, 349t–356t
rising stars, 644–645
safety considerations, 639–642
in situ reprogramming, 638
in solid tumours, 329–333
therapeutics, 136
therapy, 69, 80–81, 583–584
academia/industry collaboration to commercialising, 345t–346t
adoptive cell therapy, 69–73
CAR, 73–77
clinical trials, 303–304
commercial, value and access challenges, 359–362
perspectives, 83–84
T cell engineering timeline, 70f
targeting antigens, 326–329
transforming T cell therapies into commercial reality, 81–83
viral vector-based gene transfer, 77–80
traditional, linear medicine manufacturing and distribution model, 754f
value, 761–766
workflows, 638–639
Chimeric antigen receptor-BCMA (CAR-BCMA), 327–328
Chimeric DNA, 692–693
China
CAR-T cell research in, 348–357
clinical trials, 349t–356t
immune cell therapy development status in, 132–133, 135t
CHOP. *See* Children's Hospital Of Philadelphia (CHOP)
Christmas disease. *See* Haemophilia B (FIX deficiency)
Chronic granulomatous disease (CGD), 19–20
Chronic immunosuppressive therapy, 161
Chronic lymphocytic leukaemia (CLL), 114, 306–309, 307t
Chronic myeloid leukaemia (CML), 748
Chronic obstructive pulmonary disorder (COPD), 517–518
'Chunk theory' method, 520–521
Chylomicron levels, 716–717
CITR. *See* Centre for Islet Transplant Registry (CITR)
Claims, 691
Class I HLA molecules, 379–382, 380f
Class II HLA molecules, 379–382, 380f
Classical gene editors, 216–218, 217f
Classification Commune des Actes Médicaux (CCAM), 724–726
Clinical manufacturing, translating bench research to, 256
Clinical responsibility, 768
Clinical trial application (CTA), 176
Clinical trial design, 29
Clinical value, 762
CliniMACS Prodigy, 614
CLL. *See* Chronic lymphocytic leukaemia (CLL)
Closed-loop concept, 158
Clr genes. *See* C-lectin–related genes (Clr genes)
Cluster Analyses, 187
Clustered regularly interspaced short palindromic repeat (CRISPR), 220–221, 292, 582, 585
systems as genome editing tools, 222–223
Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9), 32–33, 224, 292–293, 412, 563–564, 582, 585–586, 637–638
collection, 232–233
engineered cell-based therapies, 778–780
gene, 196, 222, 332–333
as gene editing therapeutic, 227

Clustered regularly interspaced short palindromic repeat *(Continued)*
nucleases therapeutics, 232, 234t–235t
system, 213–214, 221, 477–478
therapeutic formulations, 228–230
CMC. *See* Chemistry, manufacturing and controls (CMC)
CML. *See* Chronic myeloid leukaemia (CML)
CMS. *See* Center for Medicare and Medicaid services (CMS)
CMV. *See* Cytomegalovirus (CMV)
CNS. *See* Central nervous system (CNS)
Codes of Federal Regulation (CFRs), 258
COGs modelling. *See* Cost of goods modelling (COGs modelling)
Coley's toxins, 527
Collaborator, 680
Collagen, 272–273, 275, 278
Collapsin response mediator protein-2 (CRMP2), 464–468, 470–472
lithium influences CRMP2 phosphorylation, 470–474
methamphetamine treatment effect, 468f
Combination chemotherapy, 548–550
Combination therapy, 94, 251–252, 559–560. *See also* Gene therapy (GT)
in cancer, 548–557, 549f
landscape analysis of targets of anti-PD-1/L1 combination trials, 552f
with NK cell–based immune therapy, 114–123
antibody-dependent cellular cytotoxicity, 118–120
cancer cell–targeting drugs, 117–118
checkpoint blockers, 121–123
cytokine combination, 114–116
radiotherapy, 116–117
targeting immune suppressive signalling, 120–121
Combinatorial antigen-sensing circuits, 635
Combined ATMPs, 587
Commercial CAR-T therapies, 757, 768
Commercial innovation, 752
Commercialisation, 243–244, 258, 264–265
of innovation, 674
Commercialization of Regenerative Medicine (CCRM), 655
Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE), 335–337
Comparator selection, 718–720
Compassionate use program (CUP), 22
Complementarity-determining regions (CDRs), 382
Complete remission (CR), 306
Complete response (CR), 633–634
Complex integrated automation devices, 263
Concanavalin-A, 52–53
Conditionally Active Biologics (CAB), 636
Conditioned media, 443–444
Conditioning induction regimen, 548–557
Consumer loan, 422
Contract Development Manufacturing Organisation industry (CDMO/CMO industry), 654–655
Contract research services, 655
Conventional malignant tumour treatments, 558–559
Conventional textile techniques, 250
Convergence innovation in inflammation and oncology, 525–530
Cooley's Anaemia. *See* Thalassaemia Major
COPD. *See* Chronic obstructive pulmonary disorder (COPD)
CoreHEM consortium, 717
Cost analyses, 618
Cost of goods modelling (COGs modelling), 606
Cost per m^2 estimates method, 616
'Cost-plus' pricing models, 761
Costimulatory
CD28 as molecule, 80–81
domain, 75
ligands, 494
NKG2D ligation, 46
receptors, 72
'Costs of resistance', 521–523
Cotherapies, 698–699
COX-2 inhibitors. *See* Cyclooxygenase-2 inhibitors (COX-2 inhibitors)
CpG-oligodeoxynucleotides (CpG-ODN), 499
CPT. *See* Current procedural terminology (CPT)
CPU. *See* Central processing unit (CPU)
CQAs. *See* Critical quality attributes (CQAs)
CR. *See* Complete remission (CR); Complete response (CR)
Cre/loxP system, 477–478
CRES. *See* Cell–related encephalopathy syndrome (CRES)
Crick Centre in London, 676

CRISPR. *See* Clustered regularly interspaced short palindromic repeat (CRISPR)
CRISPR/Cas9. *See* Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9)
Critical limb ischaemia, 722
Critical quality attributes (CQAs), 396
*Crmp*2-Knockout mouse (CRMP2-KO mouse), 469–470, 471f
CRMP2. *See* Collapsin response mediator protein-2 (CRMP2)
Cross-border access of CAR-T therapy, 773
Cross-reactivity, 47–48
CRS. *See* Cytokine release syndrome (CRS)
Cryopreservation, 755
Cryotanks, 755
CTA. *See* Clinical trial application (CTA)
CTAs. *See* Cancer-testis antigen (CTAs)
CTCAE. *See* Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE)
CTL. *See* Cytotoxic T lymphocytes (CTL)
CTL019 cell, 43
CTLA-4. *See* Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)
CUP. *See* Compassionate use program (CUP)
Curative treatments, payment and reimbursement for, 27–28
Current good manufacturing practices (cGMP), 161
  cell and tissue manufacturing infrastructure for compliance, 260
Current Good Tissue Practices (cGTPs), 258
Current procedural terminology (CPT), 723b
Customer value, 778–780
Customer/business model, 753–757
CXCL10. *See* Chemokine (C–X–C motif) ligand 10 (CXCL10)
CXCR3 receptor, 98
CYAD-101, 637–638
Cyclic GMP-AMP, 500
Cyclin-dependent kinase-5, 472
Cyclooxygenase-2 inhibitors (COX-2 inhibitors), 519
Cyclosporine, 244
Cystic fibrosis, 288
Cytokine release syndrome (CRS), 306, 315–319, 335–338, 344, 362–363, 393–394, 532, 541–544, 633–634, 639, 759
  grading scale, 336t
Cytokine(s), 54, 103, 105, 114, 342–343, 490
  combination, 114–116
  therapy, 377
Cytomegalovirus (CMV), 510–511
Cytoplasmic sensors, 500
Cytotherapies, 705, 708
Cytotoxic T cells, 303–304
Cytotoxic T lymphocytes (CTL), 41, 492
Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), 122, 545
Cytotoxicity, 119
  of NK cells, 93

D

Damage-associated molecular patterns (DAMPs), 490, 493
DAMPs. *See* Damage-associated molecular patterns (DAMPs)
DAPI. *See* 4',6-Diamidine-2'-phenylindole dihydrochloride (DAPI)
Data
  mining, 621
  privacy of CAR-T therapy, 772
  processor, 191
Daudi Burkitt's lymphoma, 46
DC. *See* Dendritic cells (DC)
DC101 antibody, 695–696
Deal terms for CAR therapies, 652–653, 653t
Deaminase enzymes to Cas9, conjugation of, 226
Decellularisation, 249, 271–272
Decellularized scaffolds, 248–249
Decentralised payer and provider systems, 728–729
Decision makers, 668–669
Decision making, 668–669
Decision Trees, 187
Decisions in development lifecycle of cell and gene therapies
  assumptions and constraints, 614–616
  autologous *vs*. allogeneic products, 599–601
  cell and gene therapy products, 624t
  challenges in commercialisation of cell and gene therapies, 599
  critical decisions, 625–626
  decision variables, parameters and assumptions, 610–614
  decisional or decision-support tools, 598, 606–622, 609f
  handling of risks and uncertainties, 619–621
  implementation, 621–622

Decisions in development lifecycle of cell and gene therapies *(Continued)*
objectives, 606–608, 607t
partnering and capacity planning decisions, 605
perspectives, 622–626
product withdrawal and divestment, 601
regenerative medicine approvals, 600f
'servitisation' of therapies, 625
solution method, 616–619
systems, 608–610
techniques and algorithm, 617t
Deep learning, 187–189
'Defensive' strategies, 548–550
Delirium, 639
Demand goal, 611
Dendritic cells (DC), 44–45, 489, 491f
adaptive immunity, 493–494
antigens for presentation, 491–492
combination therapies, 500–501
cross-presentation, 494–495
dual function, 492–494
ex vivo APC generation, 496
generation of potent, 496–497
techniques of antigen loading, 497f
in immune system network, dual role of, 489–490
innate immunity, 493–494
initiation of, 492–493
strategies to employ activated, 496f
targeting patrolling DC and releasing natural potential, 498–500
targeting cytoplasmic sensors, 500
targeting TLR agonists, 498–500
therapeutic strategies using, 495
therapy product, 136
vaccine therapy, 377
in vivo antigen loading of, 498
in vivo expansion of, 498
Deoxyribonucleic acid (DNA), 15–16
Design structure matrix (DSM), 618
Deterministic modelling, 619–620
Device Master File (MAF), 171–172
Device optimisation, 164–165
Diabetes, unmet medical need of, 157–158
Diagnosis-related group (DRG), 723, 726
4',6-Diamidine-2'-phenylindole dihydrochloride (DAPI), 249
Diffuse large B-cell lymphoma (DLBCL), 321–322, 324, 357, 583–584, 751
Dimension Therapeutics, 652–653
2,3-Dioxygenase (TDO), 533–536
'Disease in a dish' approach, 464–465
Divestment, 601
DLBCL. *See* Diffuse large B-cell lymphoma (DLBCL)
DLI therapy. *See* Donor lymphocyte infusions therapy (DLI therapy)
DMD. *See* Duchenne muscular dystrophy (DMD)
DNA. *See* Deoxyribonucleic acid (DNA)
DNA-barcode-Conjugation, 196
Donor lymphocyte infusions therapy (DLI therapy), 51, 303
L-dopa, 473–474, 483
Double-chain chimeric antibody receptor, 9–10
Downstream operations process parameters, 611–614, 612f
DP. *See* Drug product (DP)
DRG. *See* Diagnosis-related group (DRG)
DRI approach. *See* Drug resistant immunotherapy approach (DRI approach)
Drug
combinations, 565
developers, 718
development pipeline, 464–468
discovery and development, 190–191
drug/disease interactions, 190–191
Drug product (DP), 168–169
Drug resistant immunotherapy approach (DRI approach), 56–57
Drug substance (DS), 168–169
'Drugome' approaches, 563–564
DS. *See* Drug substance (DS)
DSM. *See* Design structure matrix (DSM)
Duchenne muscular dystrophy (DMD), 709
Duration of effect, 715–716

E

E:T ratio. *See* Effector cells versus tumour cells ratio (E:T ratio)
Early ADA-SCID gene therapy, 18–19
Early endosomes, 493
Early gene therapy failures, 19–20
Early Phase process development, 257
Eat-me signals, 489–490, 492
EBV. *See* Epstein–Barr virus (EBV)
ECM. *See* Extracellular matrix (ECM)
*Eco*RV enzyme, 232
Ectosomes, 439–441

'Edmonton Protocol', 158
Effector cells versus tumour cells ratio (E:T ratio), 104
EFT. *See* Embryonic-foetal transition (EFT)
EGFR. *See* Epidermal growth factor receptor (EGFR)
EGFRvIII. *See* Epidermal growth factor receptor variant III (EGFRvIII)
EIS. *See* Enterprise Investment Scheme (EIS)
Electrospinning technology, 271–272
ELIANA trial, 756–757
EMA. *See* European Medicines Agency (EMA)
Embryo, 269–270
Embryonic stem cells (ESCs), 159, 216, 246
Embryonic-foetal transition (EFT), 453
EMT. *See* Epithelial-to-mesenchymal transition (EMT)
Encapsulation, 161–162, 163t, 176–177
  limitations, 165–168
  macroencapsulation, 162–165
  microencapsulation, 162–165
Encaptra device, 164–165, 165f, 167
  host vascularisation of, 169f
ENCODE. *See* Encyclopaedia of DNA Elements (ENCODE)
Encyclopaedia of DNA Elements (ENCODE), 193–194
Endogenous insulin-producing beta cells, 157–158
Endogenous MSCs, 10–11
Endosomal sorting complex required for transport (ESCRT), 439–441
Engineered AAV vectors, 18
Engineered immune effector cells, 551, 559–560
Engineered neural tissue (EngNT), 273–274, 276f, 278
  to replace autograft, 276–278
Engineered Platelet gene therapy for haemophilia A, 419
Engineered T cell therapy, 303, 377–378, 401. *See also* Chimeric antigen receptor T cell (CAR-T); T cell receptors (TCRs)
  initial three studies of, 385–389
  MAGE-A3 experiences, 391–392
  NY-ESO-1 studies, 389–390
  perspectives, 399–402
  studies without preinfusion conditioning, 392
Engineering and Physical Sciences Research Council (EPSRC), 667–668
EngNT. *See* Engineered neural tissue (EngNT)
EngNT-CTX, 278–279
Enterprise Investment Scheme (EIS), 682, 684
Enterprise risk factors, 620
Environment, 659–663
Enzalutamide, 42
Enzymatic agents, 249
Enzyme replacement therapy (ERT), 19, 290
Epidermal growth factor receptor (EGFR), 538–539, 584
Epidermal growth factor receptor variant III (EGFRvIII), 330–331, 509, 511
Epimorphosis, 453
Episode-of-care reimbursement, 723–727
Epistemological revolution, 461–462
Epithelial-to-mesenchymal transition (EMT), 515
EPSRC. *See* Engineering and Physical Sciences Research Council (EPSRC)
Epstein–Barr virus (EBV), 103
Equipment-factored estimates, 616
Erlotinib, 548–550
ERT. *See* Enzyme replacement therapy (ERT)
Escherichia coli, 220
ESCRT. *See* Endosomal sorting complex required for transport (ESCRT)
ESCs. *See* Embryonic stem cells (ESCs)
Eteplirsen, 717
EU. *See* European Union (EU)
European Medicines Agency (EMA), 15, 28–29, 288, 290, 324, 358, 415, 435–436, 479–480, 587–588, 597–598, 634, 673–674, 748
  and gene therapies, 30t
European Union (EU), 22, 597–598, 653–654, 673–674
EV. *See* Extracellular vesicle (EV)
Evidence, 709–710, 712, 718, 728
  gap, 768
Ex vivo APC generation, 496
  loading-up with antigens, 497–498
Ex vivo delivery, 15–16
Exosomal therapy, 439–442
Exosome(s)
  engineering, 442
  large-scale manufacturing of, 442
Express Scripts, 427–428
Expressive aphasia, 639
External cell, 261
Extracellular matrix (ECM), 244–245, 261
Extracellular vesicle (EV), 439, 441
  biogenesis, 440f

F

F1 Oncology, 636
Facility costs, 616
FACS. *See* Fluorescent-activated cell sorting (FACS)
FBC. *See* Foreign body capsule (FBC)
FCB Pharmicell, 435
FcγRs receptor, 120
FDAMA. *See* Food and Drug Administration Modernisation Act (FDAMA)
FDIs. *See* Foreign direct investments (FDIs)
FHCRC. *See* Fred Hutchinson Cancer Research Center (FHCRC)
Financial markets, 668
Financial-based risk sharing, 765t
Financing history of leading companies, 642
First-generation CAR-T therapies, 633–634
First-generation CARs, 583, 692–693
  design, 74–75
  T cells, 74–75
First-line cancer chemotherapy, 548–550
Fiscal measures, 681–682
FIX deficiency. *See* Haemophilia B (FIX deficiency)
FIX-Padua, 416–418
FL. *See* Follicular Lymphoma (FL)
Flat organs, 262
'Flexible voucher' system, 28
Fluorescent proteins to Cas nucleases, conjugation of, 226–227
Fluorescent-activated cell sorting (FACS), 196, 614
Follicular Lymphoma (FL), 321–322
Fondazione Telethon, 22–23
Food and Drug Administration Modernisation Act (FDAMA), 426–427
Foreign body capsule (FBC), 167–168
Foreign body reaction, 167–168
Foreign direct investments (FDIs), 683–684
Foundation for Biomedical Research and Innovation, 750
Fourth-generation CARs, 697–699
Fraunhofer Institute for Cell Therapy, 750
Fraunhofer-Gesellschaft in Germany, 669–671
Fred Hutchinson Cancer Research Center (FHCRC), 306, 308–309, 313, 322, 343–344
Free market prices, 668
Functional agent, 462
Functional avidity of T cell, 382
Funding, 664–667
FVIII deficiency. *See* Haemophilia A (FVIII deficiency)

G

GammaDelta Therapeutics, Ltd., 56
Gammavirus, 286
GBM. *See* Glioblastoma multiforme (GBM)
GCN4 (yeast transcription factor), 697–698
GD2, 330–331, 584
GDP. *See* Gross domestic profit (GDP)
GE. *See* General Electric (GE)
Gefitinib, 548–550
Genalyte, 638–639
Gendicine, 20, 294t
Gene therapy (GT), 15–22, 201–202, 285, 409–410, 659–660, 675–676, 708–709, 712–713, 747–748, 749f, 751–752
  challenges in commercialisation of, 599
  companies, 652–653
  early ADA-SCID gene therapy, 18–19
  early development, 16–18
    vector development, 17–18
  early gene therapy failures, 19–20
  European Medicines Agency and, 30t
  factors affecting innovation in, 666f
  FDA and, 31t
  first approvals, 20–22
  future research funding, 29–32
  for haemophilia in preclinical and clinical phases, 417t
  innovative payment models, 424t
  limited patient population, 28–29
  major events in, 33f
  medicinal products, 293f
  payment models for, 764–766, 765t
  perspectives, 293–295, 428–429
  for SCD and beta thalassaemia, 413t
  second innovation wave, 292–293
  Strimvelis development, 22–28
  technology, 32–34
  time for success, 290–292
  trials, 649–650
    history, 287–290
  and value-based pricing implementation in United States, 420–428
  vector types, 286–287
  for VWD, 419–420
  worldwide gene therapy approvals, 21t

Gene Therapy Advisory Committee, 674
Gene therapy medicinal products (GTMPs), 587
Gene transfer, 77
Gene-based therapies, 7–10, 251
Gene-editing
  approaches, 82
  and drug discovery, 214
  nucleases, 215
  revolution, 233
  technologies, 581–582
    adoptive T cell therapy, 583–584
    findings, 586–591
    genome-editing technologies in cancer immunotherapy, 584–586
    materials and method, 582
    perspectives, 591–593
    principle of autonomy, 589–591
    principle of beneficence/nonmaleficence, 586–589
    principle of justice, 591
    technology description, 582–586
Gene-modified CD4+ and CD8+ T cells, 303–304
Gene-modified cells, 445
Gene-modified haematopoietic cells, 16–17
General Electric (GE), 655
General practice physician (GP), 722–723
Genetic algorithms, 187
Genetic disorders, 100
Genetic engineering, 82, 700–701
  tools, 213–214
Genetic modifications, 251
Genetically engineered MSCs, 10–11
Genetically engineered T cell therapy, 69
Genetix Pharmaceuticals, 643
Genome editing tools, 177
Genome-editing approach, 213–214
Genome-wide association studies (GWAS), 192–193
10x Genomics, 638–639
Genyzme, 651–652
Germ line cells, 586
Germ line/soma dichotomy, 449–450, 450f
German Institute for Quality and Efficiency in Healthcare (IQWiG), 718–719
Gilead, 642
GITR. *See* Glucocorticoid-induced tumour necrosis factor receptor (GITR)
GlaxoSmithKline (GSK), 15, 26, 378
Glialign project, 279
Glioblastoma, 47–48
Glioblastoma multiforme (GBM), 507, 525–527
  CAR–functionalised cell therapy in, 508–511
    CAR-T therapy, 509–511
    Chimeric antigen receptor, 507–509
    selection of clinical trials deploying, 510t
  chimeric antigen receptor–functionalised NK cell therapy, 511
  immunosuppression, 507–508
GLP. *See* Good Laboratory Practice (GLP)
Glucocorticoid-induced tumour necrosis factor receptor (GITR), 533–536
Glybera, 22, 292–295, 294t, 597–598, 751–752
Glybera, 706, 716–719
Glycogen-synthase kinase 3-beta (GSK3β), 472
O-glycosylation, 530–532
GM-CSF. *See* Granulocyte-macrophage colony stimulating factor (GM-CSF)
GmbH, 699
GMP. *See* Good Manufacturing Practice (GMP)
Good Clinical Practices, 477–478, 588
Good DNA, 285
Good Laboratory Practice (GLP), 171–172, 477–478, 588
Good Manufacturing Practice (GMP), 103, 278, 442, 477–478, 588, 616
Good Tissue Practices, 477–478
Google, 426–427
Google Charts, 622
GP. *See* General practice physician (GP)
Graft-versus-host disease (GvHD), 41–42, 94, 251, 303, 540–541, 585, 651–652
Graft-versus-leukaemia effect (GVL effect), 303
Graft-versus-tumour effect, 41–42
Granulocyte-macrophage colony stimulating factor (GM-CSF), 343, 718–719
gRNAs. *See* Guide RNAs (gRNAs)
Gross domestic profit (GDP), 660
GSK. *See* GlaxoSmithKline (GSK)
GSK3β. *See* Glycogen-synthase kinase 3-beta (GSK3β)
GSK3β inhibitors, 479–480
GT. *See* Gene therapy (GT)
GTMPs. *See* Gene therapy medicinal products (GTMPs)
Guide RNAs (gRNAs), 218, 228, 585
GvHD. *See* Graft-versus-host disease (GvHD)

GVL effect. *See* Graft-versus-leukaemia effect (GVL effect)
GWAS. *See* Genome-wide association studies (GWAS)

H

HACA. *See* Human antichimeric antibody (HACA)
Haematologic malignancies, 45–46
Haematological malignancies
  CAR-T cell therapies targeting antigens other than CD19 for, 326–329
  clinical outcome of CD19 targeted CAR-T cells in B-cell, 306–326
Haematopoietic stem cell transplantation (HSCT), 41–42, 290, 659–660
  allogeneic γδ T cell therapy in setting, 50–51
  HSCT–based therapies, 724
Haematopoietic stem cells (HSCs), 4–5, 17, 72–73, 104, 287
Haemoglobin Bart's, 410–411
Haemoglobin H disease, 410–411
Haemoglobinopathies, 410–413
Haemophilia, cell and gene therapies for, 417t
Haemophilia A (FVIII deficiency), 413–414, 419
  Engineered Platelet gene therapy for, 419
Haemophilia B (FIX deficiency), 413–414, 416
HAMA. *See* Human antimurine antibody (HAMA)
Harvard Pilgrim, 427–428
HAVCR2. *See* Mucin domain-3 protein (TIM-3)
Hayflick Limit, 452
HbA. *See* Adult haemoglobin (HbA)
HCC. *See* Hepatocellular carcinoma (HCC)
HCT/Ps. *See* Human cells, tissues and cellular-and tissue-based products (HCT/Ps)
HCV. *See* Hepatitis C virus (HCV)
HDAC. *See* Histone deacetylases (HDAC)
HDR. *See* Homologous directed recombination (HDR)
Head-to-head trials, 770
Health assessment technology bodies, 426
Health Canada, 358
Health Research Authority (HRA), 674
Health technology assessment (HTA), 712–713, 716, 718, 729
Healthcare
  planning, 663
  products and services, 721
  professionals, 759
  systems, 762–763
Heat shock protein 70 (HSP70), 441
hEG cells. *See* Human embryonic germ cells (hEG cells)
Hemophilia A, 709
Hepatitis C virus (HCV), 708–709
Hepatocellular carcinoma (HCC), 545
HER2. *See* Human epidermal growth factor receptor 2 (HER2)
Her2/neu, 584
Hereditary persistence of foetal haemoglobin (HPFH), 412
Herpes Simplex Virus (HSV), 286
hESCs. *See* Human embryonic stem cells (hESCs)
Heterodimer CD94/NKG2A, 123
HFEA. *See* Human Fertilisation and Embryology Authority (HFEA)
HIF-1A. *See* Hypoxia-inducible factor 1α (HIF-1A)
High mobility group box 1 (HMGB-1), 525–527
High performance Integrated Virtual Environment (HIVE), 359
High-cost transformative therapies, 736
  outcomes-based arrangements for, 729
High-throughput screening employing, 479
*Hin*dIII, 232
hiPSCs. *See* Human induced pluripotent stem cells (hiPSCs)
Histone deacetylases (HDAC), 545–547
HIV. *See* Human immunodeficiency virus (HIV)
HIVE. *See* High performance Integrated Virtual Environment (HIVE)
HLA. *See* Human leucocyte antigen (HLA)
HMGB-1. *See* High mobility group box 1 (HMGB-1)
Hollow spherical organs, 262
Homologous directed recombination (HDR), 213
Homologous recombination, 585
Hospital onboarding team, 760
Hospital Outlier Payment mechanisms, 726–727
Hospital readmission, 423–425
Hospital Supplemental Outlier Payment, 727
House of Lords, 674
HPFH. *See* Hereditary persistence of foetal haemoglobin (HPFH)
HPV. *See* Human papillomavirus (HPV)
HRA. *See* Health Research Authority (HRA)
HSCs. *See* Haematopoietic stem cells (HSCs)

HSCT. *See* Haematopoietic stem cell transplantation (HSCT)
HSP70. *See* Heat shock protein 70 (HSP70)
HSV. *See* Herpes Simplex Virus (HSV)
HTA. *See* Health technology assessment (HTA)
hTERT. *See* Human telomerase reverse transcriptase (hTERT)
Human anti-CD19 CAR-T cells, 80
Human antichimeric antibody (HACA), 542–544
Human antimurine antibody (HAMA), 4–5
Human Cell Atlas, 197–198
Human cell senescence, 452
Human cells, tissues and cellular-and tissue-based products (HCT/Ps), 259
Human embryonic germ cells (hEG cells), 453
Human embryonic stem cells (hESCs), 104–105, 159–160, 270–271, 453
  cell lines, 453
  pluripotency of, 457f
Human epidermal growth factor receptor 2 (HER2), 119, 509–511
Human Fertilisation and Embryology Authority (HFEA), 675
Human immune system, 69–71
Human immunodeficiency virus (HIV), 290–291, 303–304, 635
  HIV1, 17
  pools, 224–226
Human induced pluripotent stem cells (hiPSCs), 462–464, 469
  cell type stages of reprogramming and associated variables, 478t
  issues in applying, 477t
  technical, regulatory and business factors, 476–481
Human leucocyte antigen (HLA), 173, 378–379, 538–539
Human NK cells, 104–105
Human papillomavirus (HPV), 332
Human peripheral blood, NK cells in, 93
Human pluripotent stem cell lines, 453
Human telomerase reverse transcriptase (hTERT), 559–560
Human tissue regeneration regulation, 453–455
Huntington's disease, 709
Hydrogels, 250, 270–272
  encapsulation, 270–271
Hydrops fetalis. *See* Haemoglobin Bart's
4-Hydroxytamoxifen (4-OHT), 278
Hydroxyurea, 411–412
Hypothetical case studies, 620–621
Hypoxia, 507–508
Hypoxia-inducible factor 1α (HIF-1A), 519–520
Hypoxic microenvironment, 507–508

I

I-PREDICT study, 563–564
IBM, 426–427
Ibrutinib, 117
'iCas9'. *See* Inducible Cas9 ('iCas9')
ICD. *See* Immunogenic cell death (ICD)
ICER. *See* Institute for Clinical and Economic Research (ICER)
ICER Policy Summit. *See* Institute for Clinical and Economic Review Policy Summit (ICER Policy Summit)
IDO. *See* Indoleamine-2,3-dioxygenase (IDO)
IFM Therapeutics, Inc., 701
IFN. *See* Interferon (IFN)
Ig-like external domains, 95
Ig-like lectins, 95
IL13Rα2. *See* Interleukin receptor-13Rα2 (IL13Rα2)
Imaging technologies, 101
Imatinib, 748–750
IMid drug. *See* immunomodulatory drug (IMid drug)
Imlygic, 292–295, 294t
Imlygic, 377, 718–719
Immatics US, Inc., 56
Immature progenitor cells, 165–166
Immortalisation, 452–453
Immortality, 452
Immune cells, 71
  therapy development status, 124–136
    China, 132–133, 135t
    Japan, 132, 133t
    Korea, 133–136, 137t–138t
Immune checkpoints, 121
  blockade, 546f
  receptors, 550
Immune/immunity
  balance control, 92
  contexture, 396
  immune-controlled intervention, 140
  regulation, 395–396
  against staphylococcal and streptococcal Cas9, 230
  suppression for T1D, 158–159

Immuno-oncology (IO), 94, 339–341, 377, 544
Immunogenic cell death (ICD), 525–527
Immunogenic tumour cell death, 537f
Immunoglobulins, 96
Immunohistochemistry, 161
Immunomedics, Inc., 701
Immunomodulation, 437
immunomodulatory drug (IMid drug), 117
Immunoreceptor tyrosine–based inhibition motifs (ITIMs), 94–95, 123
Immunosuppression, GBM, 507–508
Immunosuppressive drugs, 244
Immunosuppressive microenvironment, 509
Immunosuppressive TME, 527, 533–536
Immunotherapeutic methods, 91
Immunotherapy, 41, 69, 507, 581–582, 633, 689
  expansion and manipulation of NK cell for clinical practice, 103–105, 107t–108t
  NK cell–based, 103–105
In situ reprogramming, 638
In situ RNA hybridisation (RNAish), 395
In situ vaccination, 536
In vivo activation and expansion of γδ T cells, 48–49
In vivo delivery, 15–16
In vivo modification, 498–500
  antigen loading of DC, 498
  expansion of DC, 498
In-process packaging, 169
IND. *See* Investigational new drug application (IND)
Indefinite replicative capacity. *See* Immortality
Independent Research and Technology Organisations (IRTOs), 678t
India National Institute of Biologicals (NIB), 358
Individualised CAR-T immunotherapy, 750
Indoleamine-2,3-dioxygenase (IDO), 102, 533–536
Induced pluripotent stem cells (iPSCs), 104–105, 173, 194, 216, 246, 269–270, 455, 464–465, 481–483
  perspectives, 481–483
  as source material for cell therapy, 173–174
Induced tissue regeneration (iTR), 456
Inducible Cas9 ('iCas9'), 697
Industrial Strategy Challenge Fund (ISCF), 681–682
Industrial Technology Research Institute in Taiwan, 669–671
Inflammation
  and cancer, 517f
  convergence innovation in, 525–530
Inflammatory diseases, 557–558
Informed consent, 589–590
Informed decision-making on cost of production, 623
Inherited monogenic diseases, 287
Inhibitory receptors of NK cells, 94–95
Initial Public Offering (IPO), 637–638
Innate immune cells, 44
Innate immunity, 493–494
  and adaptive immunity, 490
  initiation of, 492–493
Innate lymphocytes, 44
Innate Pharma, 42–43, 54
Innovate UK, 681
Innovation, 664–667, 669–672, 778–780
  barriers to, 663–669
  chasms, 663–664
  infrastructure, 676–679
  legislation and policies, 672–676
Innovation S-curves, 3, 461–462, 467–468, 470–472, 481–482
  big pharmas and radical innovation adoption, 6–8
  black swan risk, 6
  bottom-line impact of successful adoption of radical innovation, 5
  patterns in industrial product emergence, 4–5
  perspectives, 11
    hurdles and catalysts of market access, 12f
  policies and regulatory frameworks as accelerators, 8–9
  predicting technological progress, 9–11
Innovative payment models for cell and gene therapies, 424t
Innovative therapy developers, 717
Inpatient BMT-based gene therapy for Ultrarare immunodeficiency disorder, 725b
Inpatient Prospective Payment System (IPPS), 725b, 726–727
Inpatient reimbursement codes and payment models, 723–724
Input parameters, 611, 613t, 615t
Insertional oncogenesis, 339
Insight deriver, 191
Institute for Clinical and Economic Research (ICER), 715–716
Institute for Clinical and Economic Review Policy Summit (ICER Policy Summit), 422
Insulin, 157–158

insulin-delivering cell therapy, 171
insulin-producing cells, 160
INT. *See* Integrated bioprocess platform (INT)
Integrated bioprocess platform (INT), 614
Intellectual property (IP), 661–663
Inter partes review, 695
Interfering RNA approach, 215–216
Interferon (IFN), 96–97, 377
IFN α-2b, 527
IFN-γ, 119, 306–308, 321–322, 493
Interferon regulatory factor 3 (IRF3), 500
Interleukin receptor-13Rα2 (IL13Rα2), 509–510, 584
Interleukins (ILs)
IL1β, 525–527
IL-2, 71–72, 114–116, 303–304, 539–540
IL-6, 306–308, 342–343
IL-6/JAK/STAT-3 signalling cascade, 533–536
IL-12, 115–116
IL-15, 105–110, 115
IL-18, 115–116
IL-21 receptor, 114
International Organization for Standardization (ISO), 258
Internet bubble, 649–650
Intratumoural heterogeneity, 532
Intravenous infusion, 748
Investigational new drug application (IND), 171–172, 319–320, 358–359
IO. *See* Immuno-oncology (IO)
Ionic detergents, 249
IP. *See* Intellectual property (IP)
Ipilimumab, 43, 122, 529, 533–536, 544
IPO. *See* Initial Public Offering (IPO)
IPP. *See* Isopentenyl pyrophosphate (IPP)
IPPS. *See* Inpatient Prospective Payment System (IPPS)
iPSCs. *See* Induced pluripotent stem cells (iPSCs)
IRF3. *See* Interferon regulatory factor 3 (IRF3)
Irradiated EBV-transformed lymphoblastoid cell line, 104
Irradiated feeder cells, 120
IRTOs. *See* Independent Research and Technology Organisations (IRTOs)
ISCF. *See* Industrial Strategy Challenge Fund (ISCF)
Islet
cell types, 175
discoveries enabling renewable source of, 159–161
ISO. *See* International Organization for Standardization (ISO)
Isopentenyl pyrophosphate (IPP), 45
Issued claims, 695
ITIMs. *See* Immunoreceptor tyrosine–based inhibition motifs (ITIMs)
iTR. *See* Induced tissue regeneration (iTR)

J

JAK/STAT pathway, 533–536
Janus kinases (JAKs), 533–536
Japan, Immune cell therapy development status in, 132, 133t
Japan Ministry of Health, Welfare and Labour/ Pharmaceutical and Medical Devices Agency, 358
Japanese Pharmaceuticals and Medical Devices Agency (PMDA), 132
Juno Therapeutics, 325–326, 363–364, 378, 643

K

K562 cells, 103
KDR-1121 antibody, 695–696
Keytruda. *See* Pembrolizumab
KFDA. *See* South Korea Ministry of Food and Drug Safety (KFDA)
Kidney transplantation, 244
Killer immunoglobulin receptors (KIRs), 43, 94
mismatch principle, 110–111
Kite Pharma, 378, 642
Kite Pharmaceuticals, 321, 323–324, 332–333, 344–348
Knowledge economy, 669
Korea, immune cell therapy development status in, 133–136, 137t–138t
KTE-C19, 323–324
Kymriah, 293–295, 294t, 321, 605, 623

L

Laboratory-produced tissue-engineered organs, 244–245
Labour costs, 616
LAG. *See* Lymphocyte activation gene (LAG)
Lambert agreement models, 680
Lang Factor, 616
Late-Phase process development and technology, 257–258
Latin hypercube sampling, 620
Leasing model. *See* Amortisation

'Lego-like' approach, 564
Lenalidomide, 117
Lentiviral technology, 79–80
Lentiviral vector (LVV), 79, 287
Lentivirus (LV), 17, 215–216, 286, 290–291, 445
Leukapheresis, 584
Levodopa, 473–474
Lex specialis, 587–588
Licences, 651
Life Sciences Industrial Strategy, 671–674
Life-threatening side effects, 105
LILR family, 95
Limited patient population, 28–29
Liponanoparticles (LNPs), 215–216, 229
Lipoprotein lipase (LPL), 22
Lipoprotein lipase deficiency (LPLD), 706
Lithium, 462
  biological processes and downstream substrates, 464f
  drug discovery and drug development pipeline timeline, 467f
  to gain insight into bipolar disorder, 463–464
  influences CRMP2 phosphorylation, 470–474
  mechanism of action to treat lithium BPD, 464f
  reveals bipolar disorder brain architectural abnormalities, 469–470
Living drugs, 583
LN. *See* Lymph node (LN)
LNPs. *See* Liponanoparticles (LNPs)
Logarithmic scale, 3
Logistical and regulatory barriers, 423–427
  best price, 427
  capturing, integrating and analysing RWE, 426–427
  definition of value, 423–425
LOH. *See* Loss of heterozygosity (LOH)
Long Terminal Repeat (LTR), 289
Long-term follow-up component (LTFU component), 22
Longitudinal health records, 780
Loss of heterozygosity (LOH), 395
LPL. *See* Lipoprotein lipase (LPL)
lpl gene, 22
LPLD. *See* Lipoprotein lipase deficiency (LPLD)
LTFU component. *See* Long-term follow-up component (LTFU component)
LTR. *See* Long Terminal Repeat (LTR)
Luciferase, 79
LUXTURNA, 292–295
Luxturna. *See* Voretigene neparvovec
LV. *See* Lentivirus (LV)
LVV. *See* Lentiviral vector (LVV)
Ly49 gene, 95
Ly49a receptor, 95
Ly49b receptor, 95
Lymph node (LN), 494
Lymphocyte activation gene (LAG), 532
Lymphocyte subsets, 41
Lymphodepleting chemotherapy, 625

M

M&A decisions. *See* Merger and acquisition decisions (M&A decisions)
MA. *See* Marketing authorisation (MA)
mAb. *See* Monoclonal antibodies (mAb)
Machine learning, 186–187
  to predict phenotype of stem cells, 198–199
MACI, 597–598
Macrocellular evolutionary mechanisms, 532
Macroeconomics headwinds, 650–651
Macroencapsulation, 162–165, 163t
Macrophages, 98–99
MACS. *See* Magnetic-activated cell sorting (MACS)
MAF. *See* Device Master File (MAF)
MAGE, 391
  MAGE-A12 expression patterns, 391
  MAGE-A3 experiences, 391–392
'Magic bullet' design, 530–532
Magnetic-activated cell sorting (MACS), 614
Major histocompatibility complex (MHC), 41–42, 93–94, 380f, 507–508, 691
  MHC-I, 491
'Make-to-order' model, 625
Malignant disease recognition, 44–58
Mantle cell lymphoma, 321–322
Manufacturing, 103
  capacity, 753
  COGs, 607
  costs, 706–707
  manufactured scaffolds, 249–250
MAPCs. *See* Multipotent adult progenitor cells (MAPCs)
Market access, critical parameters for, 709–720
Marketing authorisation (MA), 597–598
  application, 324
  process, 588
Markets in Europe, 728–729

MART-1, 385–389
MATLAB, 622
Mature NK cells, 97
MDSC. *See* Monocyte-derived suppressor cells (MDSC); Myeloid-derived suppressor cells (MDSC)
Mechanism of action (MoA), 94
Mechanobiology, 199
Medical and clinical field in CAR-T therapy, 771
Medical Research Council (MRC), 667–668
Medicare Provider and Analysis Review (MedPAR), 725b
Medicare Severity-DRG (MS-DRG), 725b
MedPAR. *See* Medicare Provider and Analysis Review (MedPAR)
Membrane vesicles, 439–441
Memorial Sloan Kettering Cancer Center (MSKCC), 306, 308–309, 314–315, 318, 330–331, 696–697
6-Mercaptopurine, 548–550
Merger and acquisition decisions (M&A decisions), 606
Mesenchymal stem/stromal cells (MSCs), 4–5, 54, 216, 246–247, 251, 270, 436–437, 441, 536–538, 599–601, 651
  new ideas, 437–445
  next generation therapies, 438f
  therapy, 435
    allogeneic, 435–436
    conditioned media, 443–444
    exosomal therapy, 439–442
    gene-modified cells, 445
    perspectives, 445
Mesoblast, 649–650
Mesothelin cMet, 584
Metabolically hostile microenvironment, 536–538
Metachromatic leukodystrophy (MLD), 23
Metastasis, 517–518
Methotrexate, 548–550
2-Methyl-3-butenyl-1-pyrophosphate (2M3B1-PP), 49–50
MHC. *See* Major histocompatibility complex (MHC)
MIATA. *See* Minimum Information About T cell Assays (MIATA)
Microbiology, 558–559
Microclusters, 382
Microencapsulation, 162–165, 163t
Mid-Phase development targeting process methodologies, 257
Minimal residual disease-negative CR (MRD-CR), 309–313
Minimum Information About T cell Assays (MIATA), 340–341
Mitochondrial replacement therapies (MRT), 675
MLD. *See* Metachromatic leukodystrophy (MLD)
MLMT. *See* Multiluminance mobility test (MLMT)
MLV. *See* Murine leukemia virus (MLV)
MM. *See* Multiple myeloma (MM)
MoA. *See* Mechanism of action (MoA)
moDC. *See* Monocyte-derived DC (moDC)
Model validation, 621
Modern governmental industrial strategy, 669–684
  encouraging investment, 681–684
  innovation infrastructure, 676–679
  innovation legislation and policies, 672–676
  investing in science, research and innovation, 669–672
  strengthening strategic capabilities, 679–681
  UK innovation landscape assets, 677f
Moloney virus gene coding, 78
Monalizumab, 123
Monoclonal antibodies (mAb), 6–7, 110–111, 377, 525, 601, 607–608, 691
Monocyte-derived DC (moDC), 497
Monocyte-derived human macrophages cells (MOTO-CAR cells), 552–554
Monocyte-derived suppressor cells (MDSC), 54
Monokines, 116
Monorhaphis chuni, 450
Monte Carlo simulation, 620
Moore's law, 183
  for semiconductor electronics, 3
Mortality, 423–425
MOTO-CAR cells. *See* Monocyte-derived human macrophages cells (MOTO-CAR cells)
Mouse NK cells express, 101
MRC. *See* Medical Research Council (MRC)
MRD-CR. *See* Minimal residual disease-negative CR (MRD-CR)
MRT. *See* Mitochondrial replacement therapies (MRT)
MS-DRG. *See* Medicare Severity-DRG (MS-DRG)
MSCs. *See* Mesenchymal stem/stromal cells (MSCs)

MSH2. *See* MutS homologue 2 (MSH2)
MSKCC. *See* Memorial Sloan Kettering Cancer Center (MSKCC)
Mucin 1 (MUC1), 530–532
Mucin domain-3 protein (TIM-3), 122, 525–527, 533–536
Multi-attribute decision-making, 618–619
Multicellular organisms, 450
Multilayer flasks, 614
Multilingual service team, 756–757
Multiluminance mobility test (MLMT), 716
Multiple CAR-NKs, 511
Multiple endocrine hormones, 175
Multiple myeloma (MM), 327–329, 390
Multipotent adult progenitor cells (MAPCs), 270
Multispecific antigen approaches, 511
Multistem, 651
Multivesicular bodies (MVBs), 439
Murine leukemia virus (MLV), 289
Murine-based γRV, 16–17
Mutagenic clonal expansion, 19–20
MutS homologue 2 (MSH2), 46
MVBs. *See* Multivesicular bodies (MVBs)
Mycobacterium tuberculosis, 220
MyD88/CD40 activation switch, 635–636
Myeloablative preparative regimen, 390
Myelodysplastic syndrome, 19–20
Myeloid cells, 97–99
Myeloid-derived suppressor cells (MDSC), 99, 532
  suppression of NK cell activity by, 99

N

N-BP. *See* Aminobisphosphonates (N-BP)
NAMD. *See* National Association of Medicaid Directors (NAMD)
Nanorobotics (NR), 229
NanoString panels, 395
Nanovesicle exosomes (NV exosomes), 229
National Association of Medicaid Directors (NAMD), 708–709
National Cancer Institute (NCI), 73, 306, 385
National Health Service (NHS), 669
National Institute for Health and Care Excellence (NICE), 675–676, 713–714
National Institute for Health Research (NIHR), 660
National Marrow Donor Program (NMDP), 727
Natural killer cells (NK cells), 4–5, 41–42, 91–92, 490, 507–508, 511, 637–638, 691
  activation mechanisms, 96–97
  adoptive transfer, 123–124
  allogeneic, 110–111
  attack, 394
  autologous, 105–110
  and cancer, 94–102
  characteristics, 92–93
  clinical development status of CAR natural killer, 136, 139t
    perspectives, 140
  combination therapy with NK cell–based immune therapy, 114–123
  deficiency, 100–101
  development, 93
  function, 93–94, 97
  future development approach, 94
  immune cell therapy development status in Asia, 124–136
  line, 111, 112t–113t
  NK cell–based immunotherapy, 102–111
  NK-92 cell, 43
  ongoing clinical trials, 123–136, 125t–127t
  receptors and ligands, 94–96
    activating receptors, 95–96
    inhibitory receptors, 94–95
  role in cancer immunosurveillance and immunoediting, 100–102
  in tumour microenvironment, 97–100
Natural killer complex (NKC), 95
Natural killer T cells (NKT cells), 490
Natural Language Processing (NLP), 189
Natural materials, 249–250
NCI. *See* National Cancer Institute (NCI)
NCR, 96
NCSC. *See* Neural crest stem cells (NCSC)
Neoantigens, 330–332, 538–539
Neoblasts, 451
Neovascularisation inhibitors, 559–560
Nerve tissue regeneration
  allogeneic off-the-shelf replacement nerve tissue, 278–279
  cellular biomaterials, 271–272
  cellular hydrogels
    creating anisotropy in, 272–273
    stabilisation of aligned, 273–274
  EngNT to replace autograft, 276–278
  peripheral nerve tissue engineering, 274–276

perspectives, 279
stem cell therapy
applications of materials to, 270–271
for neuronal regeneration, 269
stem cells and mechanisms of action, 269–270
Net present value (NPV), 607
Network linkages, 191
Neural crest stem cells (NCSC), 276–278
Neural networks, 187–189
Neural stem cells (NSCs), 269–270
Neuro-Linguistic Programming (NLP). *See* Natural Language Processing (NLP)
Neurofibrillary tangles (NFTs), 472
Neurological diseases, 462
Neurological toxicity, 338
Neuronal regeneration, stem cell therapy for, 269
Neurons, 469
Neuroscience, 763
Neurotoxicities, 532
Neurotoxicity, 362–363
New Diagnostic and Treatment Methods Regulation reimbursement (NUB reimbursement), 726
New Technology Add-on Payment (NTAP), 726–727
New York oesophageal squamous cell carcinoma-1 (NY-ESO-1), 332, 389–390, 538–539
Next-generation
CAR-T, 635, 642
gene editor, 218, 219f
NFTs. *See* Neurofibrillary tangles (NFTs)
NHEJ. *See* Nonhomologous end joining (NHEJ)
NHL. *See* Non Hodgkin's lymphoma (NHL)
NHS. *See* National Health Service (NHS)
NIB. *See* India National Institute of Biologicals (NIB)
NICE. *See* National Institute for Health and Care Excellence (NICE)
NIH. *See* United States National Institutes of Health (NIH)
NIHR. *See* National Institute for Health Research (NIHR)
Nivolumab, 529, 533–536, 717–718
NK cells. *See* Natural killer cells (NK cells)
NKC. *See* Natural killer complex (NKC)
NKG cell line, 111
NKG2 receptor, 95
NKG2D, 637–638
ligands, 46
receptor, 96
NKRP1 receptor, 96
NKT cells. *See* Natural killer T cells (NKT cells)
NLP. *See* Natural Language Processing (NLP)
NMDP. *See* National Marrow Donor Program (NMDP)
Non hereditary diseases, 229–230
Non Hodgkin's lymphoma (NHL), 46, 315–318, 321–326
clinical outcome reported with CD19-targeted CAR-T cells, 316t
Non-small cell lung cancer (NSCLC), 55, 523, 524f
Nonadoption consequences of radical innovation, 6
Noncancer targets, 700–701
Noncurative bridge-to-BMT treatment scenario, 715–716
Nonhomologous end joining (NHEJ), 213
Nonionic detergents, 249
Nonpeptide alkylphosphates, 45–46
Nonpeptide antigens, 45
Nonstandard payment models, 728–729
Nonviral vectors, 18, 286, 292
Novartis, 344–348, 378, 427–428, 591, 605, 642
CAR-T therapy, 759
journey to CAR-T therapy, 748–751
NPV. *See* Net present value (NPV)
NR. *See* Nanorobotics (NR)
NSCLC. *See* Non-small cell lung cancer (NSCLC)
NSCs. *See* Neural stem cells (NSCs)
NTAP. *See* New Technology Add-on Payment (NTAP)
Nucleic acids, 500, 696
polymer, 694
Nusinersen, 716–717
NV exosomes. *See* Nanovesicle exosomes (NV exosomes)
NY-ESO-1. *See* New York oesophageal squamous cell carcinoma-1 (NY-ESO-1)

O

Objective response rate (ORR), 525–527
OECD. *See* Organisation of Economic Cooperation and Development (OECD)
Off-target
activity, 394
edits, 585
effects, 227–228, 231

Off-the-shelf
CAR-T cells, 344–348, 584
products, 398
therapy, 41–42, 54–55, 344–348
treatment. *See* Allogenic treatments
'Off-tumour/on-target' toxicity, 329–330
Offensive strategies, 548–550
Office of Inspector General (OIG), 727
4-OHT. *See* 4-Hydroxytamoxifen (4-OHT)
OIG. *See* Office of Inspector General (OIG)
Olovnikov hypothesis, 452
Omics
data to cell therapies, 194–195
working with omics insights, 191–196
AI for drug discovery, development and repurposing, 192f
deriving, 192–194, 193f
On target toxicity, 338–339
'On target/off tumour' toxicity, 338–339
'On-target, off-tumour' toxicity, 393–394, 639
Oncology, 564. *See also* Solid tumour oncology
checkpoint blockade to enhance antitumour immunity, 528f
convergence innovation in, 525–530
therapy, 559–560
Oncolytic viruses, 559–560
therapy, 377, 538–539
Opdivo. *See* Nivolumab
Operationen-und Prozedurenschlüssel (OPS), 724–726
Ophthalmology, 763
OPS. *See* Operationen-und Prozedurenschlüssel (OPS)
OR. *See* Overall response (OR)
Organ
failure, 243
inflammation, 17–18
Organisation of Economic Cooperation and Development (OECD), 660
Oriental medicine, 91
Ornithine transcarbamylase deficiency (OTC deficiency), 288
Orphan Act, 778–780
ORR. *See* Objective response rate (ORR); Overall response rate (ORR)
OS. *See* Overall survival (OS)
Osiris, 651–652
OTC deficiency. *See* Ornithine transcarbamylase deficiency (OTC deficiency)
Outcome-based payments, 763
models, 735t
Outcome-based pricing. *See* Value-based pricing (VBP)
Outcome-based risk-sharing models, 764, 765t
Outpatient cell therapy for critical limb ischaemia, 723b
Overall response (OR), 634
Overall response rate (ORR), 306–308, 325
Overall survival (OS), 309–313, 711
OX40 antibody, 556, 695–696

P

*p*53 gene, 20
Paediatric acute lymphoblastic leukaemia (pALL), 315–321, 764
Palisade Risk 6, 621
pALL. *See* Paediatric acute lymphoblastic leukaemia (pALL)
PAM. *See* Protospacer adjacent motif (PAM)
Pamidronate, 45–46
PAMP. *See* Pathogen-associated molecular patterns (PAMP)
Pancreatic adenocarcinoma (PDAC), 519–520
Pancreatic hormones, 175
Pancreatic progenitor
cells advantages, 174–176
pancreatic progenitor–derived in vivo differentiated grafts, 161
Panitumumab, 717–718
pAPCs. *See* Professional antigen-presenting cells (pAPCs)
Paracrine
activity of MSCs, 443
effects, 436–437
mediators, 436–437, 443
Parallel induction regimen, 548–557
Paraplatin, 548–550
Parkinson's disease (PD), 473–474
epistemic and clinical breakthroughs, 474f
revisiting established functional agent Levodopa, 473–474
Partial reprogramming, 456
Partial response (PR), 306
Partnering, 605
PASS. *See* Postauthorisation safety study (PASS)
Patent Cooperation Treaty (PCT), 689–690
Patent Trial and Appeal Board (PTAB), 695–696

Patents, 690
in CAR technology, 691–699
first-generation CARs, 692–693
second-generation CARs, 694–697, 694f
third-and fourth-generation CARs, 697–699
genetic engineering and 'universal' CAR-expressing cells, 700–701
noncancer targets, 700–701
perspectives, 701–703
and process, 690–691
U.S. Patent No. 4,224,237, 691
U.S. Patent No. 7,190,446, 694
U.S. Patent No. 7,465,741, 692
U.S. Patent No. 8,465,743, 695–696
U.S. Patent No. 9,020,587, 696
Pathobiology of cancer, 558
Pathogen-associated molecular patterns (PAMP), 490, 493
Patient
access schemes, 728
approaches to addressing patient's immune system, 176–177
autonomy, 589
diagnostics, 393
patient-and payer-centric approach, 780–781
patient-derived leukocytes, 71
population stratification, 717–718
responsibility, 766–767
value, 762
Patient-reported outcomes (PROs), 714
Pattern recognition receptors (PRR), 490
'Pay as you go' model, 707
Pay-for-performance arrangements, 729, 765t
Payers, 713
acceptance, 721
Payment
challenges and models, 727–730
for curative treatments, 27–28
models for cell and gene therapies, 764–766, 765t
schemes, 729
PBMC. *See* Peripheral mononuclear cells (PBMC)
PBMNC. *See* Peripheral blood mononuclear cells (PBMNC)
PCT. *See* Patent Cooperation Treaty (PCT)
PD. *See* Parkinson's disease (PD)
PD-1. *See* Programmed cell death-1 (PD-1)
PD-1/PD-L1 receptor/ligand system, 500–501
PD-6. *See* Programmed cell death 6 (PD-6)
PD1. *See* Cell death protein 1 (PD1)
PDAC. *See* Pancreatic adenocarcinoma (PDAC)
pDC. *See* Plasmacytoid DC (pDC)
PEC-01 cells, 171–172
PEG. *See* Polyethylene glycol (PEG)
Pembrolizumab, 529, 544–545, 717–718
Peptide-bound Major Histocompatibility (pMHC), 331–332
Peptide–HLA complex (pHLA), 379
Peptides, 491
Performance-based plans, 27–28
Performance-based pricing Value-based pricing (VBP)
Perinatal stem cells, 247
Peripheral blood mononuclear cells (PBMNC), 52–53, 103
Peripheral mononuclear cells (PBMC), 496–497
Peripheral nerve injury (PNI), 274
Peripheral nerve tissue engineering, 274–276
Personalised combination therapy treatment, 563–564
Personalised medicine, 15
PGE2. *See* Prostaglandin E2 (PGE2)
Pharmaceutical
companies, 769
responsibility, 768
developers, 712
expenditures, 770
industry, 777–778
Phase 1/2 clinical trial, 172–176
Phase 2 JULIET study, 325
Phase 3 KEYNOTE-426 clinical trial, 550
Phenylketonuria, 709
pHLA. *See* Peptide–HLA complex (pHLA)
Phospho-inositol-3 kinase (PI3K), 533–536
Phosphorylation, 464–465
PHS. *See* Public Health Service (PHS)
Phylogenetic trees, 201
PI3K. *See* Phospho-inositol-3 kinase (PI3K)
PIDs. *See* Primary immunodeficiency diseases (PIDs)
piggyBac transposon systems, 477–478
Planar culture flasks, 614
Plasmacytoid DC (pDC), 499
Plastic compression, 273–274
PLGA. *See* Poly-DL-lactide-co-glycolide (PLGA)

Pluripotent stem cell–derived islet replacement therapy
advantages of pancreatic progenitor cells, 174–176
approaches to addressing patient's immune system, 176–177
cell therapy using cadaver-derived islets and immune suppression, 158–159
discoveries enabling renewable source of islets, 159–161
encapsulation initiating circumvent requirement, 161–162, 163t
foreign body reaction and vascularisation, 167–168
iPSC as source material for cell therapy, 173–174
perspectives, 177
preclinical studies and regulatory submission, 171–172
first clinical step, 172–176
product manufacturing, 168–171
unmet medical need of diabetes, 157–158
Pluripotent stem cells, 4–5, 159, 246
PMBCL. *See* Primary mediastinal large B-cell lymphoma (PMBCL)
PMDA. *See* Japanese Pharmaceuticals and Medical Devices Agency (PMDA)
PMDA Act (2014), 8–9
pMHC. *See* Peptide-bound Major Histocompatibility (pMHC)
PMOA. *See* Primary mode of action (PMOA)
PNI. *See* Peripheral nerve injury (PNI)
Poly-DL-lactide-co-glycolide (PLGA), 559–560
Polyclonal T cells, 72–73
Polyethylene glycol (PEG), 162
microencapsulation approach, 164
Polyhormonal endocrine cells, 160
Positive externality, 668
Postauthorisation obligations, 587–588
Postauthorisation safety study (PASS), 23
Postsurgical infections, 581
PR. *See* Partial response (PR)
Precision
medicine, 717–718
oncology, 563–564
Prednisone, 548–550
Preinfusion conditioning, 394
Pricing, 427–428, 727–730. *See also* Value-based pricing (VBP)
modality, 421
system, 761
examples of pricing
Primary immunodeficiency diseases (PIDs), 16–17
Primary mediastinal large B-cell lymphoma (PMBCL), 324
Primary mode of action (PMOA), 171
PRIME. *See* Priority Medicines (PRIME)
Principle
of autonomy, 589–591
of beneficence/nonmaleficence, 586–589
of justice, 591
Priority Medicines (PRIME), 8–9, 392–393, 415–416
Private businesses, 661–663
Procedural codes, 724–727
Procedural reimbursement codes, 722–723
Process development, 256–258
phases, 257–258
Process economics, 618
Process simulations, 257–258
Process validation, 256
Prochymal/chondrogen, 651–652
Product
complexity, 261–262
development
costs, 607
systems, 608
engraftment, 172
manufacturing, 168–171
risk factors, 620
type, 610
value demonstration considerations, 712–713
withdrawal, 601
Proefficacy, 548–550
Professional antigen-presenting cells (pAPCs), 44–45, 493
Programmed cell death 6 (PD-6), 441
Programmed cell death-1 (PD-1), 122, 500–501
blockade, 533–536
function, 545
PD-1/PD-L1inhibitors, 551–552
Proinflammatory cytokines, 552–554
Proof-of-Principle/-Concept/-Activity/-Safety, 778–780
Proof-of-Relevance, 778–780
PROs. *See* Patient-reported outcomes (PROs); Public Research Organisations (PROs)
Prostaglandin E2 (PGE2), 533–536
Prostate-specific membrane antigen (PSMA), 330–331
Protein-engineered AAV, 18

Protospacer adjacent motif (PAM), 221, 637–638
Provenge, 42, 359–360, 377, 719
Proximity ligation, 196
PRR. *See* Pattern recognition receptors (PRR)
PSMA. *See* Prostate-specific membrane antigen (PSMA)
PSREs. *See* Public Sector Research Establishments (PSREs)
PTAB. *See* Patent Trial and Appeal Board (PTAB)
Public Health Service (PHS), 258
Public Research Organisations (PROs), 678t
Public Sector Research Establishments (PSREs), 678t
Public servants, 668
PubMed, 481–482, 563–564
PubMed-NCBI database, 582
Punctuated stochastic phase, 521–523

Q

Quality control (QC), 616, 753
Quality of life (QoL), 320–321
Quality Systems Regulations, 477–478
Quality-adjusted life year (QALY), 715–716
Quantum Cell Expansion System, 263

R

R&D. *See* Research and development (R&D)
r/r. *See* Relapsed or refractory (r/r)
RAC. *See* Recombinant DNA Advisory Committee (RAC)
Radiation therapy, 689
Radical innovation
  big pharmas and adoption, 6–8
  bottom-line impact of adoption, 5
  commercial emergence
    barriers to innovation, 663–669
    factors affecting innovation in cell and gene therapies, 666f
    modern governmental industrial strategy, 669–684
    organisational competencies, 665f
    perspectives, 684–685
    UK cell and gene therapy industry, 661f
  nonadoption consequences of, 6
Radiotherapy, 116–117, 559–560
RAFT absorbers, 273–274
Randomised controlled trials (RCTs), 29, 718
Rapamycin, 559–560
Rare congenital bleeding disorders (RBD), 413–414
Rat Schwann cells, 278
RBCs. *See* Red blood cells (RBCs)
RBD. *See* Rare congenital bleeding disorders (RBD)
RCC. *See* Renal cell carcinoma (RCC)
RCR/RCL. *See* Replication-competent retrovirus or lentivirus (RCR/RCL)
RCTs. *See* Randomised controlled trials (RCTs)
RDBMS. *See* Relational database management software (RDBMS)
Real world data. *See* Real-world evidence (RWE)
Real-world evidence (RWE), 420–421, 426
  approaches, 718
  capturing, integrating and analysing, 426–427
RECIST. *See* Response evaluation criteria in solid tumours (RECIST)
Recombinant DNA Advisory Committee (RAC), 332–333
Reconstructive surgery, 243
Red blood cells (RBCs), 410–411
Red face test, 781
Reexamination, 693
Regenerative Medicine, 7–9, 11, 183, 194, 243–244, 251, 453, 597, 652, 705, 778–780
  clinical translation changing paradigm, 263–265
  trials, 710–711
Regenerative Medicine Advanced Therapies (RMATs), 8–9, 392–393
Regenerative Medicine Programme, 681
Regents of University of California, 696
REGENXBIO, 652–653
Regulatory approval, 751–752
Regulatory T cells (Tregs), 46, 99, 507–508, 532, 584
Reimbursement, 409–410, 420, 422, 426, 428–429
  for cell and gene therapies, 599
  codes, 721–722
  and payment models for therapies
    affordability of advanced therapies, 708–709
    burden of illness, 718–720
    considerations, 721–727
    critical parameters for market access, 709–720
    inpatient reimbursement codes and payment models, 723–724
    manufacturing and administration costs, 706–707
    modern reimbursement systems, 721–722
    perspectives, 730–736

Reimbursement *(Continued)*
precision medicine and patient population stratification, 717–718
pricing and payment challenges and models, 727–730
procedural and episode-of-care–based reimbursement codes, 724–727
procedural reimbursement codes, 722–723
regenerative and advanced therapy clinical trials, 708f
with transformative and curative intent, 728–730, 731t–734t
program, 26
for curative treatments, 27–28
Reinsurance, 422
Relapse, 333–335
strategies to manage CD19-negative relapse, 334–335
Relapsed or refractory (r/r), 751
Relational database management software (RDBMS), 622
Renal cell carcinoma (RCC), 111, 550
Replication-competent retrovirus or lentivirus (RCR/RCL), 339
Replication-competent viruses, 339
Replication-deficient HIV-based vectors. *See* Lentiviral vector (LVV)
Replication-deficient viral vectors, 78
Representative claim, 692–693, 695–696
Research and development (R&D), 28–29, 660
Tax Credit scheme, 672–673, 682–683
Research and Innovation Organisations (RIOs), 676, 678t, 679
Response assessments, 396
Response evaluation criteria in solid tumours (RECIST), 396
Retinal pigment epithelium (RPE), 716
Retinal pigmental epithelial cells (RPE cells), 269–270
Retrospective cohort studies, 556–557
Retroviral vectors (RVs), 285
transduction, 79–80
Retroviral/retrovirus (RV), 16–17, 77, 286, 288, 290–291
gene transfer, 77
γ-Retrovirus (γRV), 16–17, 20
Revealer, 195–196
RGENs. *See* RNA-guided endonucleases (RGENs)
Ribonucleic acid (RNA), 18, 198–199, 492
RIOs. *See* Research and Innovation Organisations (RIOs)
Risk, 586, 588, 619–621, 664
factor, 588–589
sharing or managed entry agreements, 728
Rituximab, 5, 42–43, 120
RM Act. *See* Act on Safety of Regenerative Medicine (RM Act)
RMATs. *See* Regenerative Medicine Advanced Therapies (RMATs)
RMB. *See* Rocking motion bioreactor (RMB)
RNA. *See* Ribonucleic acid (RNA)
RNA interference (RNAi), 215
RNA-guided endonucleases (RGENs), 221–223
RNAi. *See* RNA interference (RNAi)
RNAish. *See* In situ RNA hybridisation (RNAish)
ROCKET trial, 314–315, 338, 361–363
Rocking motion bioreactor (RMB), 619
RPE. *See* Retinal pigment epithelium (RPE)
RPE cells. *See* Retinal pigmental epithelial cells (RPE cells)
RPE65-mediated inherited retinal disease, 720
RQR8, 636
Ruxolitinib, 118
RV. *See* Retroviral/retrovirus (RV)
RVs. *See* Retroviral vectors (RVs)
RWE. *See* Real-world evidence (RWE)

S

S-curves, 3, 614
Saccharomyces cerevisiae, 563–564
Safety, Tolerability and Efficacy of VC-01 Combination Product in Type One Diabetes trial (STEP ONE trial). *See* Phase 1/2 clinical trial
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), 15, 22–23, 290
SB-FIX gene therapy, 418
SBS technology. *See* Sequencing by Synthesis technology (SBS technology)
Scaffold
design, 247–248
implanted, 248–250
manufactured, 249–250
materials, 247–248
Scale, 611
scale up for manufacturing, 262–263
Scar tissue, 557–558

Scavenger receptors, 492
SCD. *See* Sickle cell disease (SCD)
scFv. *See* Single-chain variable fragment (scFv)
scFv-based fusion proteins, 76–77
Schmidtea mediterranea, 450
Schwann cells, 276–278
SCID. *See* Severe combined immunodeficiency (SCID)
SCID-Bg immune knockout mouse model, 160
SCID-X1. *See* X-linked severe combined immunodeficiency (SCID-X1)
Science, 669–672
SCR. *See* Stressed cell response (SCR)
sCTMPs. *See* Somatic cell therapy medicinal products (sCTMPs)
SD. *See* Stabilisation of disease (SD)
SEC. *See* Securities and Exchange Commission (SEC)
Second generation cell therapies, 41
Second generation genome editing technologies
  background, 218–220
  biologics, 214–215
  Cas9, 222
  classical gene editors, 216–218
  conjugation
    of deaminase enzymes to Cas9, 226
    of fluorescent proteins to Cas nucleases, 226–227
  CRISPR, 220–221
    based transcriptional activation and repression, 223–226
    systems as genome editing tools, 222–223
  CRISPR Cas
    collection, 232–233
    CRISPR Cas9 variants, adaptations, 223
    CRISPR-Cas9 as gene editing therapeutic, 227
    nucleases therapeutics, 232
    systems, 225f
    therapeutic formulations, 228–230
  gene editing and drug discovery, 214
  immunity against staphylococcal and streptococcal Cas9, 230
  interfering RNA approach, 215–216
  modes of delivery in context of therapeutics, 228–230
  next generation gene editor, 218
  NHEJ introduction of mutations, 228
  off-target effects, 227–228
  perspectives, 233
  purposes as tool for drug discovery, 223
  small molecules, 214
  stem cell therapy, 216
  therapeutic interventions, 230–231
Second-generation anti-CD19 CAR, 80
Second-generation CARs, 76–77, 583, 694–697, 694f
Second-generation cell-based therapies
  AI, 184–200
  big data, 184–200
  big datasets, 190–200
  perspectives, 200–202
Secure ordering, 757
Securities and Exchange Commission (SEC), 44, 651–652
Seed Enterprise Investment Scheme (SEIS), 684
Seizures, 639
Self-antigens, 330–331
Self-inactivating LV vector (SIN LV vector), 17
Sendai virus (SeV), 18, 445
Senescence, 454–455
Senolysis, 455
Sensitivity analysis, 620
Sensors, 490
Sentinels, 490
Sequencing by Synthesis technology (SBS technology), 184
Sequential induction regimen, 548–557
Servitisation of therapies, 625
SeV. *See* Sendai virus (SeV)
Severe combined immunodeficiency (SCID), 18–19, 287, 339, 659–660
sgRNA. *See* Small guide RNA (sgRNA)
Shareholder responsibility, 768–769
Shotgun cytotoxic chemotherapeutic agents, 559–560
Sickle cell disease (SCD), 410–412
  cell and gene therapies for, 413t
Sickle RBCs, 410–411
Sigilon Therapeutics, 418–419
Signal transducer and activator of transcription 3 (STAT-3), 533–536
Silent carrier state, 410–411
Silico systems, 183
Simulation platforms, 621–622
SIN LV vector. *See* Self-inactivating LV vector (SIN LV vector)
Singapore Health Sciences Authority, 358

Single-arm trial approaches, 719–720
Single-cell
genomic sequencing, 196
measurement, 196–198
sequencing of large populations, 196–198, 197f
Single-chain variable fragment (scFv), 74–75, 308–309, 692, 696
Single-nucleotide polymorphisms (SNPs), 192–193, 410
Single-objective decision-making, 618–619
Sipuleucel-T. *See* Provenge
Site-specific integration of CAR gene, 586
Skin grafting, 244–245
Sleeping Beauty transposon, 419
SMA. *See* Spinal muscular atrophy (SMA); Supplementary Motor Area (SMA)
Small guide RNA (sgRNA), 222–223
Small molecules, 214, 527–529, 533–536, 559–560, 565
Small-and medium-sized enterprises (SMEs), 669–671
SMEs. *See* Small-and medium-sized enterprises (SMEs)
SNPs. *See* Single-nucleotide polymorphisms (SNPs)
Societal pressures, 777–778
Societal responsibility, 769–771
Societal value, 762–763
Society's responsibility, 769–771
SOCS. *See* Suppressor of cytokine signalling (SOCS)
Sofosbuvir, 708–709
Solid and functioning healthcare system, 769
Solid organs, 262
Solid scaffolds, 250
Solid tumour oncology
CAR-T cells
insufficient migration and infiltration, 540–541
limitations in ability, 539–540
challenges in, 530–544
beyond checkpoint blockade, 531f
combination therapies, 548–557
enhanced killing capabilities, 541–542
few tumour-associated antigens targets, 538–539
immunosuppressive tumour microenvironment, 533–536
improved safety profile, 542–544
intratumoural heterogeneity, 532
macrocellular evolutionary mechanisms, 532
metabolically hostile microenvironment, 536–538
perspectives, 557–565
successes in checkpoint inhibitors, 544–547
therapeutic combinations road map, 562f–563f
Solid tumours, 584
cancers, 45–46
CAR-T cells in, 329–333
addition of safety switch to manage toxicity, 331
exploring potential target antigens, 330–331
optimisation of CAR-T cell to improve antitumour efficacy, 331
TCR gene therapy, 331–333
Solution method, 616–619
DSM, 618
process economics, 618
single-objective *vs*. multi-attribute decision-making, 618–619
value systems modelling, 618
'what-if' scenario analysis, 618
Somatic cell therapy medicinal products (sCTMPs), 587
SOPs. *See* Standard Operating Procedures (SOPs)
South Korea Ministry of Food and Drug Safety (KFDA), 358
South Korean FDA. *See* South Korea Ministry of Food and Drug Safety (KFDA)
Spark Therapeutics, 409, 415–416, 652–653
Specificity, 696–697
Spinal cord injury, 216
Spinal muscular atrophy (SMA), 716
SR-Tiget. *See* San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)
Stabilisation of disease (SD), 306
Standard Operating Procedures (SOPs), 257–258
Staphylococci, 227, 230
Staphylococcus aureus, 558–559
STAT-3. *See* Signal transducer and activator of transcription 3 (STAT-3)
Stem cells, 159, 245–246
and mechanisms of action, 269–270
applications of materials to, 270–271
stem cell–based study, 462, 463f
therapy, 216
therapy for neuronal regeneration, 269
transplant, 18–19
transplantations, 762–763

Stempeucel, 435–436
Stepwise gradual phase, 521–523
Stimulator of interferon genes (STING), 500
STN. *See* Subthalamic nucleus (STN)
Stochastic modelling, 619–620
Strategic alliances
  deal, 655–656
  landscape in 2017–18, 652–655
  2000s landscape, 649–650
  2010s landscape, 650–652
  perspectives, 656
Strategic checklist for new pharmaceuticals, 778–780, 779f
Strategy for UK Life Sciences, 669, 684–685
Streptococci, 227, 230, 581
Streptococcus pyogenes, 585
Stressed cell response (SCR), 493
Striatum, 474
Strimvelis, 293–295, 294t, 597–598, 706–707, 716–717, 720
  business, 26
  development, 22–28
  efficacy, 23
  payment and reimbursement for curative treatments, 27–28
    factors in treatment value and cost of drug, 27t
  registry, 23–24, 24t
  strategic alliance, 22–23
  success
    collaboration and division of expertise, 25–26
    treatment manufacturing, 26
    vector improvement, 25
Structural databases to design molecules, 190
Structured data, 189
Substantia nigra pars compacta, 474
Subthalamic nucleus (STN), 474–476
Suicide switch, 697
Sumitomo Dainippon Manufacturing Plant, 194
Sunitinib, 550
Supplementary Motor Area (SMA), 474
Supply chain in TCR–engineered T cells, 396–399
Suppressor of cytokine signalling (SOCS), 533–536
Swissmedic FDA, 358
Switches, 697–698
synNotch receptor. *See* Synthetic Notch receptor (synNotch receptor)
Synthetic
  biology approaches, 564
  gene circuits, 635
  genes, 83
  phosphoantigen BrHPP, 52
  polymers, 249–250
Synthetic Notch receptor (synNotch receptor), 635
System boundary, 608–610
  manufacturing and supply chain systems, 608–610
  product development systems, 608
Systems pharmacology, 563–564

T

αβ T cell depleted grafts (αβTCD grafts), 50
T cell depletion (TCD), 51
T cell engineering. *See also* Tissue engineering
  and CAR-T cell therapy development, 69, 80–81
    adoptive cell therapy, 69–73
    CAR, 73–77
    perspectives, 83–84
    transforming T cell therapies into commercial reality, 81–83
    viral vector-based gene transfer, 77–80
  timeline, 70f
αβ T cells, 41–42, 584
γδ T cells, 44–58
  obstacles to development and implementation of therapies, 53–54
  potential for γδ T cells as primary effectors, 48–53
    allogeneic γδ T cell therapy in setting of HSCT, 50–51
    autologous γδ T cell therapy, 49–50
    cell manufacturing strategies, 52–53
    DLI therapy, 51
    in vivo activation and expansion, 48–49
  γδ T cell–based immunotherapies, 54
T helper 1 cells (TH1 cells), 97
T lymphocyte, 696
T-bodies, 41, 583, 691
T cell receptor–engineered T cells. *See also* Engineered T cell therapy
  biomarkers and improving responses, 394–396
  clinical development considerations, 392–394
  clinical experience with, 385–392
  initial three studies, 385–389
  manufacturing and supply chain, 396–399
  therapy studies, 386t–388t

T cell receptors (TCRs), 44–45, 72, 92, 331–332, 378–379, 492, 530–532, 692, 698. *See also* Engineered T cell therapy
  chains, 382
  classes of antigens targetable by, 383t
  gene therapy to treat solid tumours, 331–333
  identifying targets and development, 383–385
  mutation frequencies, 384t
  and peptide–MHC interface, 380f
  population coverage with multiple, 381f
  structure and function, 379–382
  TCR-engineered T cell therapy, 538–539
  TCR–driven recognition, 530–532
T cells, 4–5, 378–379, 396, 583–584, 691. *See also* Chimeric antigen receptor T cells (CAR-T cells)
  engineering, 584
  growth factor, 71–72
  persistence, 71–72
  therapy, 377
    transforming into commercial reality, 81–83
T-flasks, 614
T1D. *See* Type 1 diabetes (T1D)
TAA. *See* Tumour-associated antigens (TAA)
TAA T cells. *See* Tumour-associated antigen T cells (TAA T cells)
TALENs. *See* Transcription activator-like effector nucleases (TALENs)
Talimogene laherparepvec. *See* Imlygic
TAMs. *See* Tumour-associated macrophages (TAMs)
TAN. *See* Tumour associated neutrophils (TAN)
TAP. *See* Transporter associated with antigen processing (TAP)
Target antigens, 330–331
  expression, 395
Targeted therapies, 548–550, 552–554, 558–560, 749–750
Targeting
  immune suppressive signalling, 120–121
  patrolling DC and releasing natural potential, 498–500
Task precedence constraint methodology, 614–615
TCD. *See* T cell depletion (TCD)
TCGA. *See* The Cancer Genome Atlas (TCGA)
TCR. *See* αβ T cell receptor (TCR)
TCRs. *See* T cell receptors (TCRs)
TDO. *See* 2,3-Dioxygenase (TDO)
Technological progress prediction, 9–11
Technology adoption curve, 673–674, 673f
'Technology Appraisals' network, 675–676
Tekniikan edistämiskeskus (TEKES), 669–671
TEMCELL HS, 435–436
TERT, 452
Tetrahymena, 450
TFL. *See* Transformed follicular lymphoma (TFL)
TFP. *See* Total productivity factor (TFP)
TGF-β. *See* Transforming growth factor β (TGF-β)
TH1 cells. *See* T helper 1 cells (TH1 cells)
β-Thalassaemia, 10–11
Thalassaemia Intermedia, 411–412
Thalassaemia Major, 411–412
Thalassaemia Minor, 411–412
Thalassaemia trait, 410–411
The Cancer Genome Atlas (TCGA), 194
TheraCyte device, 162, 167
Therapeutic antitumour immunity, 121
Therapeutic gene (transgene), 15–16
6-Thio-2′-deoxyguanosine (6-thio-dG), 559–560
Third-generation
  ADV vectors, 17–18
  CARs, 697–699
Third-Party/government financing, 422–423
Three-dimension
  architecture, 247–248
  bioprinting, 250
  printing, 271–272
Throughput, 611
TIC. *See* Cell Therapy Technology and Innovation Centre (TIC)
TILs. *See* Tumour-infiltrating lymphocytes (TILs)
TIM-3. *See* Mucin domain-3 protein (TIM-3)
Tisagenlecleucel, 377, 583–584, 589, 706–707, 720
Tissue engineering, 243–245, 271–272. *See also* T cell engineering
  biomaterials, 247–256
  cells in cellular and tissue therapies, 245–247
  elements of, 245f
  key considerations in applications, 245
  manufacturing, 258–263
    cell and tissue manufacturing infrastructure, 260
    cell therapy manufacturing and product complexity, 261–262
    clean room environmental classification, 261t
    regulatory environment, 258–260
    scale up for manufacturing, 262–263

process development, 256–258
regenerative medicine clinical translation changing paradigm, 263–265
translating bench research to clinical manufacturing, 256
upcoming technologies, 250–252
allogenic treatments, 251
combinatorial therapies, 251–252
genetic modifications, 251
tissue-engineered products with scaffolds, 252
vascularisation of engineered organs, 252
tissue-engineered products, 253t–255t
Tissue manufacturing infrastructure for cGMP Compliance, 260
Tissue therapy, cells in, 245–247
Tissue-engineered products, 587
with scaffolds, 252
TKIs. *See* Tyrosine kinase inhibitors (TKIs)
TLR. *See* Toll-like receptors (TLR)
TLS. *See* Tumour lysis syndrome (TLS)
TME. *See* Tumour microenvironment (TME)
TML. *See* Tumour mutational load (TML)
Tmunity, 636, 644
TNF. *See* Tumour necrosis factor (TNF)
TNF-related apoptosis-inducing ligand (TRAIL), 552–554
TNFRS. *See* Tumour necrosis factor receptor superfamily (TNFRS)
TNO. *See* Toegepast Natuurwetenschappelijk Onderzoek (TNO)
TNP. *See* 2,4,6-Trinitrophenyl (TNP)
Tocilizumab, 759
Toegepast Natuurwetenschappelijk Onderzoek (TNO), 669–671
Toll-like receptors (TLR), 498–500
TONIC clinical trial, 525–527
Total productivity factor (TFP), 668
Toxicity considerations, 393–394
Tracking platform, 757
Tracking role of mechanical forces on cell behaviour, 199
Traditional pharmaceuticals, 747
TRAIL. *See* TNF-related apoptosis-inducing ligand (TRAIL)
Transcription activator-like effector nucleases (TALENs), 214, 292–293, 585–586, 637–638
Transcyte, 597, 599, 649–650
Transformative effect, 713–714
Transformative therapy, 719, 721–722
developers and manufacturers, 736
Transformative value, 713–717
Transformed follicular lymphoma (TFL), 324
Transforming growth factor β (TGF-β), 98, 525
secretion, 120
transgene. *See* Therapeutic gene (transgene)
Translational infrastructure, 669–671
Transporter associated with antigen processing (TAP), 379
Trastuzumab, 119
Tregs. *See* Regulatory T cells (Tregs)
Trial and error process, 160
2,4,6-Trinitrophenyl (TNP), 74
TRX518, 533–536
tSCs. *See* Tumour-initiating stem cells (tSCs)
Tuberculosis vaccine, 581
Tubular hollow organs, 262
Tumour associated neutrophils (TAN), 519–520
Tumour lysis syndrome (TLS), 306–308, 335
Tumour microenvironment (TME), 507–508, 517–518, 520–521, 536–538, 545–547, 554–555
immunosuppressive, 533–536
Tumour microenvironment, NK cells in, 97–100
NK cells activity regulation by tumour cells, 99–100
regulatory T cell, 99
suppression of natural killer cell activity by MDSC, 99
suppressors effect in, 99–100
Tumour mutational load (TML), 507–508
Tumour necrosis factor (TNF), 93, 321–322
TNFα, 96–97, 525–527
Tumour necrosis factor receptor superfamily (TNFRS), 554–555
Tumour-associated antigen T cells (TAA T cells), 303
Tumour-associated antigens (TAA), 41
targets, 538–539
Tumour-associated macrophages (TAMs), 519–520
Tumour-infiltrating lymphocytes (TILs), 16–17, 71–72, 78, 385, 533–536, 554–555, 659–660
Tumour-initiating stem cells (tSCs), 529
sensitisers, 559–560

Tumours, 515–517
tumour cells, NK cells activity regulation by, 99–100
tumour-derived cytokines, 98
tumour-derived inhibitory factors, 54
tumour-specific CAR, 695
tumour-specific T cells, 73
21st Century Cures Act, 8–9, 778–780
Type 1 diabetes (T1D), 157–158
cell therapy using cadaver-derived islets and immune suppression, 158–159
Type 2 diabetes (T2D), 157
Tyrosine kinase inhibitors (TKIs), 545–547

U

UAB. *See* University of Alabama at Birmingham (UAB)
UCART123, 637–638
UCB. *See* Umbilical cord blood (UCB)
UK. *See* United Kingdom (UK)
UK Cell Therapy Manufacturing Centre, 679
UK Regenerative Medicine Platform (UKRMP), 660, 680
UL-16 binding proteins (ULBP1–6), 46
Umbilical cord blood (UCB), 19, 104
UCB-derived NK cells, 104
Uncertainties, 619–621, 712
Unencapsulated pancreatic progenitor cell implants, 164
UniQure, 416–418
United Kingdom (UK), 661, 713
innovation infrastructure, 676
treasury department, 682
United States Food and Drug Administration (US FDA), 15, 358, 583–584, 587, 633
FDA-approved CAR-T therapies, 634t
United States National Institutes of Health (NIH), 54–55, 194, 332–333
United States Patent and Trademark Office (USPTO), 690, 701–702
Universal CAR-T cell (U CAR T 19 cell). *See* 'Off-the-self' CAR-T cells
'Universal' CAR-expressing cells, 700–701
'Universal' donor approaches, 82
University of Alabama at Birmingham (UAB), 51, 56–57
Unmanipulated allogeneic T cell therapy, 41–42
Unstructured data, 189
Untranslated regions (UTRs), 222
Upstream operations process parameters, 611–614, 612f
US FDA. *See* United States Food and Drug Administration (US FDA)
USPTO. *See* United States Patent and Trademark Office (USPTO)
UTRs. *See* Untranslated regions (UTRs)
Vaccinia, 286
'Valleys of death', 663–664
Valoctocogene roxaparvovec, 415
Value, 423–425
of CAR-T therapies, 761–766
societal, 762–763
systems modelling, 618
Value-based pricing (VBP), 420–421, 423
implementation in United States, 420–428
logistical and regulatory barriers, 423–427
Vascular endothelial growth factor (VEGF), 507–508, 538–539, 557
Vascularisation, 167–168
VBA. *See* Visual basic for application (VBA)
VBP. *See* Value-based pricing (VBP)
VC-01 STEP ONE clinical trial, 176
VCTs. *See* Venture Capital Trusts (VCTs)
Vectibix. *See* Panitumumab
Vectors
development, 17–18
of gene therapy, 286–287
improvement in Strimvelis, 25
VEGF. *See* Vascular endothelial growth factor (VEGF)
'Vein-to-vein' cell journey, 756
Venture capital
incentives, 672–673
investment, 683–684
Venture Capital Trusts (VCTs), 682
Very good partial response (VGPR), 327–328
Vesicular stomatitis virus (VSV), 78–79
VGPR. *See* Very good partial response (VGPR)
Vincristine, 548–550
Viral gene transfer, 80
Viral vectors, 286, 292, 755–756
viral vector-based gene transfer, 77–80
viral vector–mediated methods of GT, 32–33
'Virtual patient' concept, 780
Virus
production, 78–79
virus-infected cells, 47–48
Virus-like particles (VLP), 499

Visual basic for application (VBA), 621
Vitruvian networks, 655
VLP. *See* Virus-like particles (VLP)
von Willebrand disease (VWD), 413–414, 419
  gene therapy for, 419–420
Voretigene neparvovec, 427–428
Voretigene neparvovec, 706–707, 716, 718–719
Voretigene neparvovec-rzyl. *See* LUXTURNA
VSV. *See* Vesicular stomatitis virus (VSV)
VWD. *See* von Willebrand disease (VWD)
Vγ9Vδ2+ T cells, 46
Vδ1+ T cells, 46–48
Vδ2+ T cells, 45–46

W

WAS. *See* Wiskott–Aldrich syndrome (WAS)
Weighted sum technique, 619
Weismann barrier, 450, 451f
Weismann hypothesis, 450
Western medicine', 91
'What-if' scenario analysis, 618
White blood cells, 747–748
WHO. *See* World Health Organization (WHO)
William's antagonistic pleiotropy, 451–452
Wiskott–Aldrich syndrome (WAS), 19–20
World Health Organization (WHO), 463–464, 777–778

X

X-linked severe combined immunodeficiency (SCID-X1), 19–20, 288, 290
  gene therapy trial, 289
Xenogeneic antigen, 249
Xenograft breast tumour model, 119

Y

Yamanaka protocol, 477–478
YESCARTA, 293–295, 693

Z

Zalmoxis, 293–295, 294t
Zidovudine, 559–560
Zinc finger nucleases (ZFNs), 214, 292, 412, 585–586, 637–638
Ziopharm Oncology, 635–636
Zoledronate, 45–46
Zoledronate alone and in combination with IL-2 (ZOL/IL2), 48–49
Zolgensma, 293–295
ZUMA-1 trial, 323–324, 341, 362–363
ZUMA-3 trial, 314–315
Zwitterionic detergents, 249
Zynteglo, 293–295
Zytiga. *See* Abiraterone acetate